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SUMMARY 
 
Pancreatic cancer represents less than 3% of cancers diagnosed each year in the 
United Kingdom yet despite this low number, it is the fifth highest cause of death 
by cancer. This situation has changed little in the past few decades with median 
survival barely altering between 1971 and 2007. The availability of well 
characterised in vivo models that histologically recapitulate pancreatic ductal 
adenocarcinoma (PDAC) have revolutionised the field of PDAC research. These 
models not only recapitulate the central epithelial component of human pancreatic 
cancer but also the incredibly complex microenvironment, a feature for which 
PDAC is well known. Due to the failure of therapies targeting the neoplastic 
epithelial cells within PDAC, increasing interest has been given to targeting the 
tumour microenvironment. The tumour microenvironment is extremely complex 
and consists of both cellular and non-cellular components and in PDAC exhibits a 
number of characteristic features including the presence of pancreatic stellate 
cells. Work in our lab has also highlighted stromal constituents such as lysyl-
oxidase and tenascin C which are vital for PDAC viability and/or metastasis. In 
recent years increasing numbers of stromal targets have been evaluated in mouse 
models of PDAC with varying success. To date work characterising the stromal 
changes elicited by targeted therapies has utilised methods which we believe lack 
the required fastidiousness required to obtain reliable and meaningful results. In 
this work we have established reliable methods for stromal characterisation, we 
have established methods to characterise the expression of tenascin C on formalin 
fixed specimens and we have applied these methods to determine the changes 
elicited by stromal targeting therapies. 
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OBJECTIVES 
 
In this study we aimed to establish methods to reliably characterise the 
composition of the tumour microenvironment. We aimed to evaluate the 
expression of tenascin C in our murine models of PDAC and determine its 
importance in both these models and in human disease. Finally we aimed to utilise 
these methods to determine the effects of lysyl-oxidase inhibition and CXCR2 
inhibition on the stroma in murine models of PDAC. 
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Chapter 1 
Introduction 
 
1.1 Biology of the pancreas 
The pancreas is both an endocrine and an exocrine gland, the endocrine pancreas 
being composed of the islets of Langerhans and the exocrine pancreas being 
composed of ducts and acini. These acini connect to the gastrointestinal tract 
through a system of ducts which converge eventually joining the common bile duct 
which enters the duodenum. The ducts are lined by a simple cuboidal epithelium 
surrounding a central lumen (see Fig. 1). 
 
1.2 Pancreatic cancer 
Pancreatic cancer represents less than 3% of cancers diagnosed each year in the 
United Kingdom (http://www.cancerresearchuk.org/cancer-info/cancerstats/). Despite this low number, 
it is the fifth highest cause of death by cancer with a median survival post-
diagnosis of only 6 months and a five year survival rate of less than 5%. This 
situation has changed little in the past few decades with median survival barely 
altering between 1971 and 2007. Patients are often diagnosed late with 
aggressive and metastatic cancer making the disease particularly difficult to treat. 
For this reason, surgical resection is possible for only 20% of pancreatic cancer 
patients. Even in patients with surgically resectable tumours who receive adjuvant 
chemotherapy the five year survival rate only increases from 5% to 15-20%.   
 
Over the same time period during which the prognosis for pancreatic cancer has 
remained unchanged other tumour types such as melanoma have seen dramatic 
increases in survival as a result of the development of therapies that target specific 
molecular alterations within the cancer cells themselves (Jang and Atkins 2013; 
Yauch and Settleman 2012). This approach is yet to yield similar results in 
pancreatic cancer with the current standard-of-care chemotherapeutic gemcitabine 
producing only a minimal survival increase in addition to its palliative effects.  
 
The most common cancer affecting the pancreas is Pancreatic Ductal 
Adenocarcinoma (PDAC), with the majority of cases being sporadic. A number of 
risk factors have been associated with PDAC including; breast cancer type 2 
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(brca2) and liver kinase B1 (lkb1) germline mutations (Jaffee, Hruban et al. 2002). 
These risk factors however only account for around 5% of PDAC cases.  
 
In common with a number of other cancers, pancreatic cancer is characterised by 
a series of early preneoplastic lesions. These lesions are called pancreatic 
intraepithelial neoplasia (PanIN) and occur in three stages, PanIN 1, 2 and 3 (see 
Fig. 1). The PanIN1 stage however is divided into PanIN1A and PanIN1B, defined 
by specific histological characterisics (Hruban, Goggins et al. 2000; Hruban, Adsay 
et al. 2001; Kern, Hruban et al. 2001). PanIN1A lesions are characterised by flat 
epithelial lesions composed of tall columnar cells which have basally situated 
nuclei and abundant supranuclear mucin. PanIN1B lesions although similar to 
PanIN1A lesions demonstrate a papillary, micropapillary or basally 
pseudostratified architecture. PanIN2 lesions may be flat but are generally 
papillary and must exhibit nuclear abnormalities with loss of polarity, 
hyperchromatism, nuclear crowding and/or anisokaryosis. PanIN3 lesions show 
greater nuclear abnormalities and disorganisation than PanIN2 lesions with duct 
epithelial cells appearing to “bud off” into the lumen of the duct, loss of cell polarity, 
abundant mucin production and increased/abnormal mitoses. Finally carcinoma 
occurs when neoplastic cells invade through the basement membrane. 
Carcinomas may further progress with loss of differentiation, generation of a 
marked stromal reaction and ultimately disseminated metastatic disease.  
 
With KRas being mutated in over 90% of cases and genes such as p16INK4A and 
p53 being mutated in over 50% of cases a genetic progression model has been 
described for PDAC (Hruban, Wilentz et al. 2000; Almoguera, Shibata et al. 1988; 
Smit, Boot et al. 1988; Hruban, van Mansfield et al. 1993; van Es, Polak et al. 
1995). KRas mutation alone in mouse models of pancreatic cancer is capable of 
reproducing the stepwise progression to PDAC seen in human patients (Hingorani, 
Perticoin et al. 2003) however this model has a long latency suggesting a 
requirement for further mutations, such as loss or mutation of p53, in order to allow 
progression to PDAC. 
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Figure 1: Overview of the evolution of PDAC 
Initially KRas mutation alone is sufficient to allow PanIN 1 formation. Gradual evolution 
subsequently occurs with the accumulation of further mutations allowing progression through 
PanIN stages to adenoma and eventually adenocarcinoma. (Images by Jennifer Morton). 
 
 
 
 
 
1.3 KRas and MAPK signalling 
KRas is a small GTP-binding protein and an important component of the MAPK 
signalling pathway. Ras when released from its association with GDP is able to 
bind GTP and subsequently activate downstream signalling predominantly through 
Raf, MEK and ERK. Importantly oncogenic forms of Ras are constitutively active 
and have been shown to trigger transformation, invasion and angiogenesis (Ellis 
and Clark 2000).  
 
1.4 p53 
Encoded by the gene TP53, p53 has a vital role in regulating the cell cycle and 
conserving the stability and integrity of the genome (Strachan and Read, 1999). 
Under situations of stress, such as DNA damage or hypoxia, activation of p53 
permits its translocation to the nucleus where it modulates the transcription of a 
wide variety of gene targets. This altered transcription results in quiescence, 
senescence or apoptosis (Shaw, Bovey et al. 1992; Diller, Kassel et al. 1990). 
TP53 mutation occurs in 50-70% of human PDAC following an initiating KRas 
mutation. Mutation of p53 does not necessarily result in the loss of p53 protein 
expression, in fact commonly it results in the expression of a stable gain-of-
function p53 protein that when present specifically promotes metastasis (Morton, 
Timpson et al. 2010).    
 
1.5 Genetically engineered mouse (GEM) models of pancreatic cancer 
The availability of well characterised in vivo models that histologically recapitulate 
pancreatic ductal adenocarcinoma have revolutionised the field of PDAC research. 
These models not only recapitulate the central epithelial component of human 
                    
Normal Duct PanIN 1 PanIN 2 PanIN 3 PDAC 
18 
 
pancreatic cancer but also the incredibly complex microenvironment, the 
importance of which will be discussed in detail in this thesis. As such they provide 
a unique opportunity, unavailable in vitro, to develop a deeper understanding of 
the processes governing the composition of the microenvironment as well as the 
ability to trial targetted therapies, often combinatorial, and determine their 
therapeutic potential.  
 
The models used in this work have been previously described and include the 
Pdx-Cre, LSL-KrasG12D, LSL-Trp53R172H, LSL-Trp53loxP, CXCR2-/- and Tenascin C-
/- mouse strains (Hingorani, Perticoin et al. 2003; Olive, Tuveson 2004; Jackson, 
Willis et al. 2001; Jamieson, Clarke et al. 2012). The main mouse model used in 
this work is the KPC model previously described by Hingorani et al. 2003. This 
model utilises Pdx driven Cre recombinase in conjunction with LSL-KrasG12D and 
LSL-Trp53R172H. The resulting expression of the Cre recombinase enzyme under 
the control of the Pancreatic and duodenal homeobox 1 promoter results in 
recombination and expression of KrasG12D and LSL-Trp53R172H within pancreatic 
tissues.  
 
1.6 Tumour microenvironment 
Due to the failure of therapies targeting the neoplastic epithelial cells within PDAC, 
increasing interest has been given to targeting the tumour microenvironment, a 
characteristic for which PDAC is well known (Feig, Gopinathan et al. 2012). Many 
epithelial cancers are able to induce a desmoplastic reaction with the 
accumulation of stromal cells and their products around the tumour epithelium. 
Pancreatic cancer, particularly PDAC, shows a particularly prominent 
desmoplastic reaction which can account for up to 90% of the tumour volume. 
 
The tumour microenvironment is an extremely complex “ecosystem” consisting of 
both cellular and non-cellular components (Feig, Gopinathan et al. 2012). The 
non-cellular fraction is made up of an extracellular matrix (ECM) including 
structural proteins such as collagens and fibronectin as well as soluble factors and 
enzymes such as cytokines, growth factors and proteinases. The cellular 
components of the tumour microenvironment include; myofibroblasts (activated 
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fibroblasts), inflammatory/immune cells, blood vessels and pancreatic stellate cells 
(Feig, Gopinathan et al. 2012).  
In addition to the high percentage of the tumour that is made up by stroma; PDAC 
is also unique in the composition of that stroma. The pancreas, similar to the liver, 
contains a population of stellate cells which, upon activation, are considered vital 
in the production of the characteristic desmoplastic reaction seen in PDAC (Apte, 
Park et al. 2004).  
 
Pancreatic stellate cells in the normal pancreas are located surrounding the base 
of pancreatic acinar cells and are characterised by a central cell body and long 
cytoplasmic processes (Apte, Haber et al. 1998). Quiescent pancreatic stellate 
cells contain large numbers of cytoplasmic lipid droplets that are high in vitamin A; 
these are lost once a stellate cell becomes activated (Apte, Haber et al. 1998). 
Pancreatic stellate cells are also characterised by the presence of Glial Fibrillary 
Acidic Protein (GFAP), desmin, vimentin, nestin and synemin (Wehr, Furth et al. 
2011; Apte, Park et al. 2004). Upon activation pancreatic stellate cells take on a 
myofibroblast-like phenotype expressing alphaSMA (Apte, Park et al. 2004). They 
are highly motile and contractile and have a high mitotic index. They are thought to 
be responsible for the production of a wide variety of ECM proteins (e.g. collagen 
I, III, XI, fibronectin, periostin, tenascin C), matrix metalloproteases (MMPs), 
neurotrophic fators (e.g. NGF, Ach), growth factors and cytokines (e.g. PDGF, 
FGF, TGFβ, CTGF, IL-1beta, IL-8, VEGF) and are therefore seen to be centrally 
placed in orchestrating the desmoplastic reaction characteristic of PDAC (Apte, 
Park et al. 2004). Additional roles for stellate cell derived myofibroblasts in immune 
suppression have also been highlighted by Fearon et al. in which ablation of 
fibroblast activation protein alpha (FAP) positive cells, a population of alphaSMA 
positive myofibroblasts, permitted immunological control of tumour growth 
(Kraman, Bambrough et al. 2010).  
 
One further feature that characterises the PDAC microenvironment is the low 
density, poorly functional vascular supply within the tumour (Provenzano, Cuevas 
et al. 2012). It is this poor vascular supply in conjunction with the desmoplastic 
reaction that is thought to play a major role in limiting the efficacy of current 
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cytotoxics, such as gemcitabine, through limited drug delivery and hypoxia 
induced drug resistance (Provenzano, Cuevas et al. 2012). 
 
As well as being incredibly complex in its composition, the tumour 
microenvironment is also in constant flux. This flux is controlled and coordinated 
by continuous crosstalk between the neoplastic cells and the environment, 
involving a wide variety of autocrine and paracrine signalling pathways including 
TGFβ, Shh, CXCLs, HGF/Met, FGFs, IGF-1 and EGF among others (Neesse, 
Michl et al. 2011). Additionally there are also direct interactions between structural 
ECM molecules and neoplastic cells through cell surface receptors such as 
integrins which signal via focal adhesion complexes and in turn via the actin 
cytoskeleton (Chung, Tan et al. 2012). This cross-talk results in the production of 
enzymes such as lysyl-oxidase and MMPs, alterations in the quantity and quality 
of structural ECM molecules such as collagen and tenascin C, alterations in the 
immune cell infiltrate and alterations in the levels of chemokines and cytokines. 
This constant cross-talk is vital in many areas of tumourigenesis, tumour 
progression, invasion and metastasis. 
 
Increasingly therapies targeting stroma in PDAC are being explored in mouse 
models of PDAC and in human disease. Clinical trials with marimastat an MMP 
inhibitor showed no improvement compared to gemcitabine alone whereas recent 
work in mice has highlighted new potential targets with inhibition of hedgehog 
signalling and enzymatic depletion of hyaluronan separately enhancing delivery of 
chemotherapy agents to pancreatic tumours through suggested “stromal 
softening” and increased vascular delivery of chemotherapy agents (Bramhall, 
Rosemurgy et al. 2001; Moore, Goldstein et al. 2007; Provenzano, Cuevas et al. 
2012; Olive, Jacobetz et al. 2009; Jacobetz, Chan et al. 2013). Unfortunately these 
studies although showing altered vasculature and increased gemcitabine delivery 
did not extensively characterise stromal changes in response to hedgehog 
signalling inhibition or hyaluronan depletion.   
 
1.7 Available methods for tumour microenvironment characterisation 
With the increasing interest in stromal targeting in cancer therapy, particularly in 
PDAC, there have been increasing numbers of publications evaluating the effects 
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of different stromal targeting therapies (Olive, Jacobetz et al. 2009; Provenzano, 
Cuevas et al. 2012; Jacobetz, Chan et al. 2013; Ijichi, Chytil et al. 2011). 
Unfortunately the methods used in these publications vary greatly in their 
fastidiousness. Some groups have used FACS analysis to quantify cellular 
constituents of tumours, others have used Western blot and qPCR analyses to 
determine levels of non-cellular stromal constituents and others have used 
histological assessment to determine either cellular or non-cellular constituents. 
FACS analysis alone provides robust counts of cellular constituents of tissues 
however it provides no information regarding tissue organisation and architecture 
and there are also a multitude of issues surrounding tissue selection and 
preparation for analysis. Similar difficulties arise with Western-blot or qPCR 
analysis for non-cellular constituents as without histological assessment there is 
no confirmation of the piece of tissue actually being analysed or its organisation 
and architecture. Broadly speaking the histological methods used to date involve 
subjectively selecting areas with highest staining and then selecting small 
numbers of representative fields on which to score the stromal constituent of 
interest. From these selected fields an average is taken which is assumed to 
represent the tumour as a whole.  
 
1.8 Important stromal targets established within our lab  
Work by Jen Morton and Bryan Miller using in vitro screening techniques in 
combination with microarray data from murine pancreatic cancer models (both 
metastatic and non-metastatic) and human pancreatic cancer data has previously 
highlighted potential stromal targets within PDAC including, tenascin C, lysyl-
oxidase and CXCR2 signalling. As such we have applied a number of stromal 
targeting therapies to the KPC model of PDAC and have shown significant effects 
on survival in the KPC model.  
 
1.9 Tenascin C 
The tenascin family has four members: tenascin C, tenascin R, tenascin X and 
tenascin W. These members all share a characteristic modular structure with an 
oligomerization domain followed by EGF-like repeats, fibronectin (FN) type III 
repeats and a fibrinogen globe (Chiquet-Ehrismann 2004). In the case of tenascin 
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C and R alternative splicing can lead to the generation of multiple isoforms that 
contain additional FN type III repeats. 
Tenascin C is produced in response to a wide variety of cellular signals such as in 
states of hypoxia under the control of the transcription factor HIF-1α or in response 
to mechanical strain provided by the stiff stroma present within tumours (Jones 
and Jones 2000).  
Tenascin C has a number of receptors and mechanisms through which it signals 
to cells. These include signalling via integrins, EGFR, c-MET, TLR4, annexin II 
and through mechanotransduction by direct cytoskeletal rearrangements. It has 
also been shown to modulate TGFβ, Notch and WNT signalling pathways. One 
mechanism by which tenascin C modulates the WNT signalling pathway is via 
downregulation of Dkk1 a known inhibitor of the WNT pathway (Ramos, Chen et 
al. 1997; Sriramarao, Mendler et al. 1993; Yokosaki, Palmer et al. 1994; Varnum-
Finney, Venstrom et al. 1995; Yokosaki, Monis et al. 1996; Iyer, Tran et al. 2008; 
Midwood, Sacre et al. 2009; Brosig, Ferralli et al. 2010; Thomasset, Lochter et al. 
1998; Taraseviciute, Vincent et al. 2010; De Wever, Nguyen et al. 2004).  
Tenascin C has been shown to be expressed in the haematopoietic stem cell 
environment and the hair follicle bulb (Klein, Beck et al. 1993; Kloepper, Tiede et 
al. 2008) and is therefore considered to be an important component within the 
stem cell niche. Tenascin C has also been shown to be overexpressed in tumour 
associated stroma in a variety of cancers including pancreatic cancer (Juuti, 
Nordling et al. 2004; Bourdon, Wikstrand et al. 1983; Chiquet-Ehrismann, Mackie 
et al. 1986). Tenascin C is involved in many of the steps of tumorigenesis from 
early tumour development through to metastatic spread and colonisation. 
Work by Bryan Miller in our lab has shown the importance of tenascin C to 
pancreatic cancer cell lines growing in vitro. By using sh-RNA to block production 
of tenascin C by the tumour cells he has shown a significant decrease in cell 
viability. Tenascin C production by tumour cells has also been shown to be vital to 
breast cancer cells upon initial metastatic colonisation of the lungs. It has been 
shown that inhibiting tenascin C production by metastatic tumour cells at any time 
point up to 21 days post tail vein inoculation results in apoptosis of tumour cells 
and regression of any establishing micrometastases. After 21 days, inhibition of 
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tenascin C production by tumour cells had no effect on metastasis growth. It has 
been suggested that this is because the production of tenascin C which is initially 
undertaken by the colonising tumour cells themselves switches over to the 
mesenchymal cells in response to stimulation by the now established metastatic 
cells (Oskarsson, Acharyya et al. 2011). In contrast to these findings which 
highlight the importance of epithelial tenascin C production, it is generally 
considered that the source of tenascin C in epithelial tumours is the mesenchymal 
cells themselves. Indeed, it has been shown that fibroblasts produce tenascin C 
when co-cultured with neoplastic epithelial cells (Chiquet-Ehrismann, Kalla et al. 
1989). 
A major function of tenascin C is modulation of the adhesion status of cells. In 
turn, the state of cell adhesion is thought to modulate pathways controlling 
genomic stability. It is therefore possible that tenascin C through modulation of the 
adhesion status of cells may indirectly have an effect on genomic stability (Tlsty 
1998; Chiquet-Ehrismann and Tucker 2011). Indeed it has been shown that 
molecules with known functions in controlling genome stability such as H2AX and 
Brad1 are down-regulated in the presence of tenascin C in glioblastoma cells 
(Ruiz, Huang et al. 2004) and that tenascin C rich environments favour the 
development of tumours (Thomasset, Lochter et al. 1998).  
In addition to promoting genomic instability, the altered state of adhesion mediated 
by tenascin C also aids tumour cell migration. Tenascin C was initially shown to be 
an anti-adhesive molecule inhibiting in vitro tumour cell adherence to fibronectin. 
In fact it is increasingly apparent that tenascin C is able to specifically modulate 
adhesion status which results in an intermediate adhesion state in tumour cells 
thus allowing migration as opposed to firm attachment or total loss of adhesion. 
(Chiquet-Ehrismann, Kalla et al. 1988; Wenk, Midwoos et al. 2000; Murphy-Ullrich 
2001). 
Epithelial-mesenchymal transition (EMT) is a process utilised by epithelial cells 
developmentally to aid tissue formation and remodelling. EMT is characterised by 
loss of cell adhesion and increased cell mobility with additional loss of epithelial 
markers such as E-cadherin. Tenascin C appears to have a significant role in the 
induction of EMT as it has been consistently linked with cancer cells undergoing 
EMT and is vital in injury induced EMT in the lens epithelium of the eye (Dandachi, 
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Hauser-Kronberger et al 2001; Tanaka, Sumioka et al. 2010). EMT is normally 
under tight control as it is vital to tissue remodelling and development however it is 
also a process utilised by tumour cells allowing migration and invasive behaviours. 
Tenascin C has also been associated with increased tumour cell proliferation. It 
has been shown that melanoma sphere growth is severely diminished in the 
absence of tenascin C. High levels have also been demonstrated at the invasive 
edges of breast cancer where there is also a significantly higher proliferation rate 
(Fukunaga-Kalabis, Martinez et al. 2010; Jahkola, Toivonen et al. 1998). 
In addition to its functions triggering growth and migration, tenascin C is also pro-
angiogenic and able to stimulate endothelial cells to acquire a sprouting phenotype 
and become migratory (Canfield, Schor et al 1995; Chung, Murphy-Ullrich et al. 
1996). In any tissue, cells must reside within 100µm of a capillary blood vessel and 
this limitation inhibits tumour growth unless the tumour can induce the formation of 
new blood vessels (Bouck, Stellmach et al. 1996). Tenascin C has been shown to 
play an important role in stimulating angiogenesis in a number of models. 
Importantly, in vivo, it has been shown that xenograft tumours grown in tenascin C 
deficient mice had significantly reduced vasculature compared to xenografts grown 
in control animals. This reduced vasculature was due to the altered regulation of 
VEGF expression by tenascin C (Tanaka, Hiraiwa et al. 2004)  
Finally tenascin C has also been linked to chemotherapy resistance in a number of 
cancers including; melanoma, breast cancer and pancreatic cancer. Tenascin C 
has been shown to induce gemcitabine resistance in pancreatic cancer through 
annexin II signalling and activation of PI3K/Akt and ultimately activation of NF-kB 
(Gong, Lv et al. 2010; Fukunaga-Kalabis, Martinez et al. 2010; Wang, Liu et al. 
2010; Helleman, Jansen et al. 2008). 
Due to the wide range of roles that tenascin C plays in the microenvironment of 
tumours and the importance of tenascin C to tumour cells in culture and at 
metastatic sites we aim to further characterise tenascin C expression patterns in 
our models of pancreatic cancer and the changes in expression elicited by 
different microenvironment targeting strategies. We aim to determine the 
importance of tenascin C in human disease and determine the similarities in 
tenascin C expression between human disease and the KPC model.  
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1.10 Lysyl-oxidase 
ECM remodelling is a constant but highly regulated process in normal tissue 
development (Baker, Cox et al. 2011). Malignant cell growth is ordinarily 
suppressed by the normal microenvironment through the provision of appropriate 
forces that govern normal tissue organisation, cell growth, adhesion and migration. 
The absence of these normal forces in tumour ECM supports malignant cell 
proliferation, motility and adhesion (Weaver, Petersen et al. 1997; Paszek, Zahir et 
al. 2005). Enzymes that control ECM remodelling, which include members of the 
LOX family, are frequently either upregulated or downregulated in both tumour and 
stromal cells in various types of cancer (Payne, Hendrix et al. 2007; Zitka, 
Kukacka et al. 2010). Lysyl-oxidase (LOX) is a member of a multigene family with 
five members; LOX, LOXL1, LOXL2, LOXL3 and LOXL4. LOX is a secreted 
copper-dependent amine oxidase which functions to catalyse the cross-linking of 
collagens and elastins in the ECM resulting in increased tissue stiffness and 
tensile strength (Kagan and Trackman 1991). It is secreted as a proenzyme and 
subsequently activated by BMP-1. LOX family members have paradoxical roles as 
both tumour suppressors and metastasis promoters although many of the tumour 
suppressive roles of LOX have been attributed to the LOX-pro-peptide rather than 
LOX itself (Kagan and Li 2003). LOX has been shown to be elevated in invasive 
and metastatic breast cancer, has been validated as a prognostic marker in head 
and neck cancer and through inhibition with beta-aminoproprionitrile it has been 
shown to be vital to the invasion of melanoma cell lines in vitro (Kirschmann, 
Seftor et al. 2002; Erler, Bennewith et al. 2006; Le, Harris et al. 2009). LOX has 
been found to be highly expressed in stromal cells surrounding mammary ductal 
carcinoma in situ and increased tissue stiffness has been shown to promote 
progression to malignancy in in vivo models of breast cancer (Decitre, Gleyzal et 
al. 1998). It has also been suggested that LOX dependent collagen cross-linking is 
required for the provision of a microenvironment capable of supporting metastatic 
cell colonisation at distant sites (Erler, Bennewith et al. 2006; Erler, Bennewith et 
al. 2009). The progression to malignancy driven by LOX induced tissue stiffness is 
mediated primarily by altered focal adhesions, growth factor receptor signalling 
and altered cytoskeletal-dependent cell contractility (Butcher, Alliston et al. 2009; 
Discher, Janmey et al. 2005; Levental, Yu et al. 2009; Yeung, Georges et al. 
2005). LOX also promotes the secretion of VEGF both in vitro and in vivo and 
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inhibition in an in vivo breast cancer model resulted in decreased intra-tumoral 
blood vessel numbers (Baker, Bird et al. 2013). In breast cancer and head and 
neck cancer upregulation of LOX closely correlates with hypoxia which is itself well 
known for its ability to enhance both metastasis and resistance to both 
chemotherapy and radiotherapy (Erler, Bennewith et al. 2006). LOX acts in 
conjunction with a wider repertoire of ECM molecules and has been shown to 
interact with fibronectin which in turn increases the catalytic activity of LOX. 
Finally, secreted LOX has been shown to recruit inflammatory cells to distant sites 
thereby helping to establish suitable niches for metastatic cells (Erler, Bennewith 
et al. 2009). Work in our lab has shown that lysyl-oxidase inhibition in the KPC 
model of PDAC leads to a significant increase in survival. As such we aim to 
characterise the stromal changes elicited by this treatment both alone and in 
conjunction with gemcitabine therapy. 
1.11 CXCR2 signalling 
The link between inflammation and tumorigenesis, tumour maintenance and 
tumour progression is well established. Patients with a history of chronic 
pancreatitis have a seven fold increased risk of developing PDAC (Duell, Casella 
et al. 2006) and patients with ulcerative colitis have a twenty fold increased risk of 
colorectal cancer which is reduced 50% by NSAID use (Xie and Itzkowitz 2008).   
CXCR2 ligands are not produced in normal pancreatic tissue but have been 
shown to be highly expressed in cases of pancreatitis. Additionally CXCR2 
expression has been noted in up to 65% of surgically resected human pancreatic 
tumours and expression is associated with poor survival (Kuwada, Sasaki et al. 
2003; Li, King et al. 2011; Wente, Keane et al. 2006; Baggiolini, Dewald et al. 
1994; Takamori, Oades et al. 2000).  
CXCR2 is a G-protein-coupled cell surface receptor which binds to a number of 
low molecular weight chemotactic chemokines. Chemokines play important roles 
in the development of tumours and metastases by modifying the tumour immune 
response through co-ordinating leukocyte infiltration, angiogenesis and acting as 
growth factors (Murphy 2001; Raman, Baugher et al. 2007; Singh, Sadanandam et 
al. 2007). 
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CXCR2 is commonly found on neutrophils although it is also expressed on 
monocytes, dendritic cells, macrophages, endothelial cells, bone marrow derived 
endothelial progenitor cells, myeloid derived suppressor cells, mast cells, 
fibroblasts and can also be induced in tumour cells by activated oncogenes 
(Heidemann, Ogawa et al. 2003; Strieter, Burdick et al. 2006; Li, Cheng et al. 
2011; Soehnlein, Drechsler et al. 2013; Hallgren and Gurish 2011; Ijichi, Chytil et 
al. 2011; Sharma, Nawandar et al. 2013; Feijoo, Alfaro et al. 2005; Marotte, Ruth 
et al. 2010). 
CXCR2 predominantly interacts with ELR+ (glutamic acid-leucine-arginine) 
chemokines, including CXCL1, 2, 3, 4, 5, 6, 7 and 8. These chemokines are all 
proangiogenic and stimulate neutrophil chemotaxis (Li, Cheng et al. 2011; 
Rainczuk, Rao et al 2012; Ahuja and Murphy 1996). 
Multiple studies to date have shown that CXCR2 participates in chronic 
inflammation, sepsis, lung pathology, atherosclerosis, neuroinflammation and has 
critical roles in angiogenesis, tumourigenesis and metastasis of colorectal cancer, 
melanoma, lung cancer, prostate cancer, pancreatic cancer and head and neck 
cancers (Stadtmann and Zarbock 2012; Veenstra and Ransohoff 2012; Gabellini, 
Trisciuoglio et al. 2009; Baier, Wolff-Vorbeck et al. 2005; Singh, Singh et al. 2010; 
Ohri, Shikotra et al. 2010; Reiland, Furcht et al. 1999; Liu, Yang et al. 2011; 
Mestas, Burdick et al. 2005; Wang, Hendricks et al. 2006; Matsuo, Ochi et al. 
2009; Yang, Rosen et al. 2010; Han, Jiang et al. 2012; Li, Cheng et al. 2011; Li, 
King et al. 2011; Wente, Keane et al. 2006). 
The roles of inflammatory cells within the tumour microenvironment are varied with 
cells capable of being either tumorigenic or tumour suppressive. Macrophages and 
neutrophils for example in their pro-tumourigenic M2 or N2 phenotype may 
promote tumour angiogenesis, matrix breakdown and tumour cell mobility as well 
as producing oxidative bursts with the release of reactive oxygen species (ROS) 
that have many roles in tumourigenesis and maintenance but importantly are also 
mutagenic (DeNicola, Karreth et al. 2011; Sica and Mantovani 2012; Mentzel, 
Brown et al. 2001; Benelli, Morini et al. 2002; Van Coillie, Van Aelst et al. 2001; 
Nozawa, Chiu et al. 2006).  
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As well as through the indirect actions of inflammatory cells, CXCR2 has also 
been shown to directly promote angiogenesis with CXCR2 signalling vital to both 
endothelial cell and endothelial progenitor cell mobilisation and chemotaxis (Li, 
Cheng et al. 2011).  
Due to a central role in the co-ordination of the PDAC microenvironment the 
CXCR2 signalling pathway provides a clear target requiring evaluation for the 
treatment of PDAC. Work in our lab has shown a significant increase in survival in 
KPC mice treated with CXCR2 inhibitors. We therefore aim to determine the 
significant effects this inhibition is having on the tumour microenvironment.  
1.12 Project aims 
Given the importance of the tumour microenvironment and the increasing use of 
stromal targeting therapies we aim to establish rigorous methods for the 
quantification of stromal constituents. Given the importance of tenascin C we also 
aim to investigate the role of tenascin C in PDAC. Finally we will utilise these 
methods and staining procedures to evaluate the stroma of the models of PDAC 
used in our lab and the changes elicited by targeted stromal therapies.  
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Chapter 2 
MATERIALS AND METHODS 
2.1 In vivo experiments  
All experiments were performed in accordance with UK Home Office guidelines 
and the EU directive 2010 with local ethical approval. Mice were maintained under 
non-barrier conditions and given a standard diet [CRM (E) expanded diet from 
Special Diets Services; Cat nº 801730] and water ad libitum.  
 
Mice were examined three times per week for the development of pancreatic 
tumours. These signs include; hunched back, central abdominal distension, weight 
loss and/or palpable tumour. Once an endpoint was reached mice were 
euthanized and necropsied and tissues collected. Some mice developed skin 
papillomas and in these cases, the papilloma was measured three times weekly 
and once it reached 1.5cm in diameter the mouse was sacrificed. These rules 
were all clearly defined in the project licence as approved by the Home Office. 
 
2.2 Mouse genotyping  
Mice were genotyped externally using the service provided by Transnetyx 
(http://www.transnetyx.com/). The company uses a proprietary method based on 
real time PCR and DNA hybridisation to determine which alleles are present in the 
mice.  
 
2.3 Drug treatments 
Mice were selected according to genotype and Pdx1-Cre, KrasG12D/+; Trp53R172h/+ 
mice were randomised to treatment or control groups. Mice were aged to 70 days 
at which time they were commenced on the randomised treatment. Gemcitabine 
(LC labs) made up in phosphate buffered saline (PBS) was given at 100mg/Kg 
twice weekly via intraperitoneal injection (IP). Scrambled 14 amino acid sequence, 
‘scrambled pepducin’ (Genscript) made up in saline was given 200µl 
subcutaneously (SC), ½i-pal peptide (Genscript), a CXCR2 inhibiting peptide, 
‘pepducin’ was given 200µl subcutaneously daily. ½i-pal peptide is a cell-
penetrating lipopeptide directed against the third intracellular loop of the CXCR2 
G-protein coupled receptor and results in selective inhibition (Kaneider, Agarwal et 
al. 2005). Lox blocking antibody (Lox-Ab) and isotype control (kind donation by 
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Janine Erler) made up in saline were given 100 µl IP daily. Drug doses utilised 
were consistent with those previously published (Jamieson, Clarke et al. 2012; 
Erler, Bennewith et al. 2006; Morton, Timpson et al. 2010). 
 
2.4 Tissue sampling 
Pancreas, lungs, liver, spleen and other tissues where appropriate were collected 
and fixed as necessary. Subsequent to fixation all samples were embedded in 
paraffin, sectioned at 5-10µm and stained with haematoxylin and eosin prior to 
microscopic analysis. 
 
2.5 Fixation protocols 
2.5.1 Long Fixation 
The tissues were incubated in 4% formalin [Leica; Cat nº 3800600E] for 24 hours 
before processing and paraffin embedding. 
 
2.5.2 Methacarn Fixation 
A solution of methanol [Sigma; Cat nº 32213], chloroform [Fisher Scientific; Cat nº 
C4960/PB17] and acetic acid [Sigma; Cat nº 695092] was made fresh at a ratio of 
4:2:1 respectively and used to fix tumour tissue samples for no more than 24 
hours. Tissues were then placed in formalin overnight before being processed and 
paraffin embedded.  
Methacarn fixation was undertaken for tumours requiring MPO staining. 
 
2.6 Histology 
Mouse tissues were embedded and cut by the Beatson Institute histology services. 
Routine histochemistry and immunohistochemistry (IHC) was performed by the 
Beatson Institute histology services except IHC for CD31, GFAP (mouse and 
human) and Tenascin C (mouse and human). Routine IHC was performed for CD3 
(Abcam, ab16669 rabbit monoclonal), alphaSMA (Abcam, ab15734 rabbit 
polyclonal), F4/80 (Abcam, ab16911 rat monoclonal), MPO (Abcam, ab9535 rabbit 
polyclonal), cleaved caspase 3 (Abcam, ab4052 rabbit polyclonal).    
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2.7 Immunohistochemistry on paraffin sections 
Slides were de-waxed for a minimum of 7 minutes in xylene and rehydrated for 2 
minutes each in decreasing concentrations of ethanol (100% - 95% - 70%) before 
finally being washed in dH2O. After immunohistochemistry, counterstaining was 
performed. Following which slides were dehydrated by immersion in increasing 
concentrations of ethanol (70%-95%-100%) before a final immersion in xylene for 
5 minutes. After dehydration slides were then mounted with a coverslip. 
 
2.7.1 CD31 
Sections were de-waxed as described previously. Antigen retrieval was performed 
by placing slides in pre-heated Citrate buffer (Thermo scientific) in a pressure 
cooker for 20 minutes. Following heating, pressure was released and slides were 
allowed to cool in the solution for 60 minutes at room temperature (RT). 
Endogenous peroxidase activity was blocked by incubation in 3% hydrogen 
peroxide (Fluka) in de-ionized water. Slides were washed in Tris-Buffered Saline 
and Tween 20 (TBST). Non-specific binding was then blocked by incubation with 
5% normal goat serum (NGS) for 30 minutes at RT. Primary anti-CD31 antibody 
(Abcam, ab28364 rabbit polyclonal) was applied overnight at 4oC at a 1/100 
dilution in 5% NGS. After washing in TBST, secondary antibody (Vector ABC Kit) 
was applied for 30 minutes at  a dilution of 1/200 in 5% NGS. After washing, signal 
amplification was performed using the ABC Complex (Vector ABC Kit), applied for 
30 minutes. After washing, positivity was then visualised with DAB, slides were 
washed in dH2O and counterstained and mounted as described previously.  
 
2.7.2 Tenascin C (anti-human)  
Sections were de-waxed as described above and antigen retrieval was performed 
using Proteinase K antigen retrieval for 7mins. Endogenous peroxidase activity 
was blocked as described above and non-specific binding was blocked with 5% 
NGS for 30 minutes at RT. Primary anti-Tenascin C antibody (Abcam antiTNC 
clone BC-24 ab6393) was applied and slides incubated overnight at 4oC at a 
dilution of 1/2000 in 5% NGS. After washing in TBST, secondary antibody (Vector 
ABC Kit) was applied for 30 minutes at  a dilution of 1/200 in 5% NGS. After 
washing, signal amplification was performed using the ABC Complex (Vector ABC 
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Kit), applied for 30 minutes. After washing, positivity was then visualised with DAB, 
slides were washed in dH2O and counterstained and mounted as described 
previously.  
 
2.7.3 Tenascin C (anti-mouse) 
Sections were de-waxed as described above and antigen retrieval was performed 
boiling slides in 1L of 1mM EDTA pH 8 for 20 minutes . Slides were allowed to 
cool for 20 minutes before endogenous peroxidase activity was blocked as 
described above. Slides had non-specific binding blocked with 5% NGS for 30 
minutes at RT before primary anti-Tenascin C antibody (Sigma, anti-TNC T3413 
rabbit polyclonal) was applied overnight at 4oC at a dilution of 1/2000 in 5% NGS. 
Slides were washed in TBST and secondary antibody (Vector ABC Kit) was 
applied for 30 minutes at  a dilution of 1/200 in 5% NGS. After washing, signal 
amplification, DAB positivity visualisation and mounting of the slides were 
performed as described previously.  
 
2.7.4 Glial acidic fibrillary protein (GFAP) 
Sections were de-waxed as described above and antigen retrieval was performed 
by placing slides in pre-heated Citrate buffer in a pressure cooker for 20 minutes. 
Following heating, pressure was released and slides were allowed to cool in the 
solution for 60 minutes at room temperature (RT). Endogenous peroxidase activity 
was blocked as described above and then washed in Tris-Buffered Saline (TBS). 
Non-specific binding was blocked with incubation in MOM mouse Ig blocking 
reagent for 1hour. Next slides were incubated in MOM diluent for 5 minutes before 
incubation in anti-GFAP (mouse monoclonal GA5 cell signalling) 1:50 in MOM 
diluent for 30 minutes at RT. Slides were washed in TBS before incubation in 
MOM biotinylated anti-mouse IgG reagent (Vector labs) for 10 minutes at RT. After 
washing; signal amplification, DAB positivity visualisation and mounting of the 
slides were performed as described previously.  
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2.8 Primary cell culture 
2.8.1 Medium for cell culture 
DMEM [Gibco; Cat nº 21969] with 10% Fetal Bovine Serum [PAA; Cat nº A15-
101], 1% Penicillin-Streptomycin [Gibco; Cat nº 15070], and 2mM L-Glutamine 
[Gibco; Cat nº 25030]. 
 
2.8.2 PDAC, primary cell line establishment and culture 
Pancreatic tumour tissue was collected in PBS at necropsy. The tissue was then 
homogenised with a scalpel blade and placed in 5mL of medium and shaken for 
30 seconds. The supernatant containing PDAC cells was collected, placed in a 
75cm2 flask [NUNC; Cat nº 153732] and a further 10mL of DMEM was added. The 
cells were cultured at 37ºC in a humidified 5% CO2 atmosphere until reaching 90% 
confluence at which time they were split using trypsin dissociation . 
 
2.9 Subcutaneous tumour growth in mice 
Primary cell lines derived from C57Bl/6 PDAC tumours were suspended in PBS 
and injected subcutaneously into the flank of control C57Bl/6 or Tenascin C-/- 
mice on a C57Bl/6 background. 1,000,000 cells were injected per mouse. Mice 
were monitored three times a week and tumours were measured from 6mm size. 
Mice were culled when tumours ulcerated or exceeded 15mm in size. The tumour 
was removed along with the overlying skin and underlying abdominal muscle and 
fixed in 10 % neutral buffered formalin pinned on wax discs. Organs (pancreas, 
liver, spleen and lungs) were also collected and evaluated for evidence of 
metastasis.  
 
2.10 Orthotopic models of pancreatic cancer 
Primary cell lines derived from C57Bl/6 PDAC tumours were suspended in 
matrigel (BD biosciences) and injected orthotopically into the tail of the pancreas 
of C57Bl/6 mice and Tenascin C-/- mice by Dr J Morton. 100 cells were injected 
per mouse.  
 
Mice were examined three times per week for the development of pancreatic 
tumours. These signs include; hunched back, central abdominal distension, weight 
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loss and/or palpable tumour. Once an endpoint was reached mice were 
euthanized and necropsied and tissues collected. 
 
2.11 Scoring: 
All scoring was performed blinded, counting 30 non-consecutive x20 magnification 
field of view (FOV) or 60 x40 magnification FOV always avoiding areas of necrosis 
except where necrosis itself was being scored. For cell counts numbers of positive 
staining cells per FOV were counted, for other immunostaining quantification either 
pixel counting or semiquantitative methods were used as described below. 
 
2.11.1 Necrosis scoring: 
Whole representative slides of tumours were scored at X20 magnification and 
average percentage necrosis was determined for each tumour. Necrosis was 
defined by set histological characteristics on haemotoxylin and eosin staining.  
These included; nuclear changes (pyknosis, karyorrhexis, karyolysis, and nuclear 
absence), cytoplasmic changes (early increased eosinophilia advancing to pale 
pink ghost like appearance), cell rupture (with release of dark basophilic nuclear 
remnants and eosinophilic protein). Necrotic areas may also contain RBCs in 
areas of haemorrhagic necrosis. 
 
2.11.2 Immunohistochemistry pixel quantification: 
30 x20 magnification images were taken at random from a representative slide 
from each tumour. The microscope (Olympus BX51) was optimised before taking 
complete sets of images therefore all images were taken with identical light levels 
and condenser setup. A manual exposure of 720µs and ISO 1600 were set as 
fixed parameters and all images were saved as TIFF files to standardise image 
quality. Finally all images were white balanced. 
 
Once acquired immunostaining was quantified using Adobe Photoshop (version 5; 
Adobe Systems, San Jose, CA) using a method that has been previously 
described (Lehr, van der Loos et al. 1999). Briefly, in photoshop with the picture 
open, click window option in the task bar and open the histogram window. Once 
this window is open click on the expand icon in the top right corner of the 
histogram window and select expanded view this will then display the total number 
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of pixels in the image and once a selection is made will show the number of 
selected pixels. Next click on the select option on the top bar of the photoshop 
window and click on colour range. Use the colour dropper within the colour range 
window to select the colour of interest and then alter the tolerance “fuzziness” 
setting to achieve a selection setting where the highlighted stained tissue is 
appropriate. This adjustment is made possible as the selected area is 
automatically highlighted on the image and therefore allows close control of the 
process. Once optimised this setting may then be saved as an .AXT file extension 
and reused for every image to be scored in a group. For each image selection the 
total number of stained pixels can then be recorded and the total staining 
represented as a percentage of the entire image in µm2 or cm2. 
2.12 Statistics: 
2.12.1 Scoring experiments: 
Three to eight mice per group were used in order to comply with guidelines 
recommended by “the three Rs”. These guidelines summarised as Refine, Reduce 
and Replace promote the ethical use of animals in research. Due to low numbers 
data cannot be assumed to be normally distributed and therefore non-parametric 
statistical tests are most appropriate. Here a Mann-Whitney test which allows the 
comparison of small groups of mice was used to determine the presence of 
statistically significant differences between groups. 
 
2.12.2 Tissue microarray analysis  
A human pancreatico-biliary tissue microarray was created within the West of 
Scotland Pancreatic Unit, University Department of Surgery, Glasgow Royal 
Infirmary. All patients gave written, informed consent for the collection of tissue 
samples, and the local Research Ethics Committee approved collection. All cases 
had undergone a standardized pancreaticoduodenectomy. A total of 1500 cores 
from a total of 224 cases with pancreatico-biliary cancer (including 119 pancreatic 
ductal adenocarcinomas) with a full spectrum of clinical and pathological features 
were arrayed in slides. At least 6 tissue cores (0.6mm diatmeter) from tumour and 
2 from adjacent normal tissue were sampled. Complete clinical follow up data was 
available for all cases within the TMA. 
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2.12.3 TMA histoscoring 
Tenascin C levels were scored based on staining intensity and area of positive 
staining stroma using a weighted histoscore (Morton, Timpson et al. 2010). The 
histoscore was calculated based on the sum of (1x% weak staining)+(2x% 
moderate staining)+(3x% strong staining), therefore providing a semi-quantitative 
classification of tenascin C levels in TMA cores. Tenascin C expression was 
defined as either high or low either being above or below the median histoscore 
value.  
 
2.12.4 TMA survival analysis 
Kaplan-Meier survival analysis was used to analyse the overall survival from the 
time of surgery and a log-rank test was performed to compare length of survival 
between the resulting two curves. 
 
2.12.5 TMA correlation  
Correlation between parameters within the TMA data set was determined using 
Spearman’s Rank-Order Correlation Coefficient. 
 
2.13 RNA microarray analysis 
Microarray analysis was performed on request by Nigel Jamieson at the Cancer 
Research Microarray Facility, Paterson Institute for Cancer Research, University of 
Manchester. 40ng of RNA was amplified using WT-Ovation Pico RNA amplification 
system (NuGEN, San Carlos, CA) with subsequent labelling and hybridisation to 
HG_U133 Plus 2.0 arrays (Affymetrix, Santa Clara, CA) using the FL-Ovation 
cDNA Biotin Module v2. Full datasets have been made public in MIAME VICE 
http://bioinformatics.picr.man.ac.uk/vice/Welcome.vice. Accession code is 
GE_PA(4). 
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Chapter 3 
Results 
3.1 Establishing a method for quantification of stromal constituents in the 
KPC model 
Given the interest in targeting stroma it was first important to carefully characterise 
and develop reliable methods to quantify the stromal constituents within our 
models of PDAC. Previous work characterising the stromal constituents of various 
models including the KPC model of PDAC is limited and methods of quantification 
vary in their fastidiousness. Previous work characterising stromal characteristics 
such as intratumoural microvessel density have subjectively identified three to five 
representative fields of view and counted the stromal constituent of interest in 
these fields (Ijichi, Chytil et al. 2011; Olive, Jacobetz et al. 2009). The count from 
these three to five fields is then used to represent the entire tumour. Due to the 
inherent subjectivity of selecting representative fields of view our first aim was to 
establish methods that provided more objective quantification of stromal 
constituents for the tumours as a whole. 
To establish a reliable method I began by counting all non-consecutive fields of 
view in a single tumour at either X20 or X40 magnification depending on the ability 
to reliably identify stromal constituents at each magnification. During these 
counting procedures I calculated a running mean and the standard error and 
graphically it was possible to see when a suitable estimate of the mean had been 
reached for each constituent such that a truly representative value had been 
determined. I found that, for any stromal constituent, counting 30 fields of view 
was sufficient to generate a representative count (See Fig. 2). The procedure of 
counting 30 fields of view at x20 magnification generally sampled the majority of 
any given tumour and even in larger tumours 30 fields of view never accounted for 
less than half of a tumour. When counting at x40 magnification 30 fields of view 
was still adequate at generating a stable and reliable mean. However given the 
smaller field size I decided to count 60 fields of view such that the area of tumour 
sampled still accounted for over half of the tumour. 
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Figure 2: Counting 30 non-consecutive fields of view reliably quantifies any 
stromal constituent within a tumour. 
Representative graphs for single tumours showing consecutive FOV counts (blue line), running 
mean (red line) and running mean +/- standard error (green and purple lines), a) CD31,   b) F4/80, 
c) MPO quantification and d) Sirius red quantification. CD31, F4/80 and Sirius red quantification 
were performed at x20 magnification and MPO at x40 magnification.   
a)   
 
b) 
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c) 
 
d) 
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3.2 Characterising the stroma of normal pancreata and KPC PDACs 
I first performed initial stromal characterisation of normal pancreata and KPC 
PDAC tissue and in doing so validated staining techniques and highlighted 
significant constituents of the KPC tumour stroma. 
3.2.1 Establishing the normal presence of immune cells within normal 
pancreata and KPC PDAC stroma 
Utilising characteristic cellular and nuclear morphology and MPO immunopositivity 
I have shown that, as expected, neutrophils are not a normal stromal constituent of 
the pancreas whereas they are present in the stroma of KPC tumours. I have also 
shown that in KPC PDACs as opposed to normal pancreata there are large 
numbers of F4/80 positive macrophages but only small numbers of CD3 positive T 
cells (see Fig. 3). 
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Figure 3: Establishing the normal presence of neutrophils (MPO), 
macrophages (F4/80) and T cells (CD3) within normal pancreata and KPC 
PDAC stroma 
Representative images of MPO, F4/80 and CD3 immunostaining in normal murine pancreata and 
in KPC PDAC tissue. Note the lack of immune cell infiltrate in normal pancreata (n=5-8 for each 
stain).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal Pancreas - MPO KPC PDAC - MPO 
Normal Pancreas – 
F4/80 
KPC PDAC – F4/80 
Normal Pancreas – CD3 KPC PDAC – CD3 
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3.2.2 Determining the presence of apoptosis and necrosis in normal 
pancreata and KPC PDACs 
Utillising the characteristic appearance of necrotic tissue and positivity of cells for 
cleaved caspase 3 it is apparent that apoptosis and necrosis are absent in the 
normal pancreas compared with KPC PDACs (see Fig. 4). 
 
Figure 4: Determining the presence of apoptosis and necrosis in normal 
pancreata and KPC PDAC tissue 
Representative images of cleaved-caspase 3 immunostaining (arrows) and H&E characteristics of 
necrosis (dashed black line) in normal pancreata and KPC PDAC tissue. Note the lack of apoptosis 
and necrosis in normal pancreata (n=5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal Pancreas – Caspase 3 KPC PDAC – Caspase 3 
Normal Pancreas – H&E KPC PDAC – H&E 
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3.2.3 Characterisation of myofibroblasts/stellate cells in KPC models of 
PDAC 
Utilising alphaSMA immunohistochemistry I have confirmed that in the normal 
pancreas there are small numbers of alphaSMA positive cells. These cells are 
predominantly perivascular smooth muscle cells as would be expected. I have also 
shown that there are large numbers of alphaSMA positive activated myofibroblasts 
in KPC PDACs (see Fig. 5). As previously discussed pancreatic stellate cells are 
considered to be the primary source of alphaSMA positive cells in both human 
PDAC and mouse models of PDAC. Unfortunately alphaSMA is not a specific 
marker for activated stellate cells as other cell types will also stain for this marker. 
These include; pericytes, smooth muscle cells and any other activated 
myofibroblast not originating from a pancreatic stellate cell. Due to the lack of 
specificity of alphaSMA as a marker of stellate cell origin I looked to use GFAP 
expression which is generally considered to be a more specific marker of 
pancreatic stellate cells. Using cell morphology, tissue location and GFAP staining 
of normal murine pancreata and both human and KPC PDAC tumour tissue I have 
shown that GFAP specifically stains both Schwann cells and pancreatic stellate 
cells within the normal murine pancreas (as expected for cells of neural crest 
origin) (see Fig. 6). I have also shown that there are GFAP positive cells present in 
both KPC and human PDAC tissue (see Figs 7 and 8 respectively). Using GFAP 
and alphaSMA staining on serial sections of KPC PDAC tissue it is also clear that 
there are significantly more alphaSMA positive cells than GFAP positive cells (see 
Fig. 9). 
 
Figure 5: Characterisation of alphaSMA positive cells within normal 
pancreata and KPC PDAC tissue 
Shows representative images of alphaSMA staining within normal pancreata and KPC PDAC 
tissue. Notice the immunopositivity of cells surrounding vessels within the normal pancreas 
consistent with perivascular smooth muscle cells (see arrows) (n=5). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Normal Pancreas – alphaSMA KPC PDAC – alphaSMA 
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Figure 6: Stellate cells within normal murine pancreas 
Shows a representative X20 magnification image of GFAP stained murine pancreatic tissue. The 
Inset image represents the highlighted red box showing a periacinar, GFAP positive pancreatic 
stellate cell (n=3). Inset shows magnified image of GFAP positive “stellate” cell in periacinar 
location. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7: Stellate cells in pancreatic tumour tissue in KPC mice. 
Shows representative X40 magnification images of GFAP stained tumour tissue (n=5). 
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Figure 8: Stellate cells in pancreatic tumour tissue in human PDAC. 
Shows representative X40 magnification images of GFAP stained human PDAC tissue (n=2). 
Arrow points to GFAP positive spindle shaped “stellate” cell. 
 
 
 
Figure 9: Stellate cells in pancreatic tumour tissue in KPC mice. 
Shows representative X10 magnification images of GFAP and alphaSMA staining on consecutive 
tumour tissue sections (n=3). 
 
 
 
 
 
 
 
 
 
 
 
 
GFAP stained KPC tumour AlphaSMA stained KPC tumour 
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3.2.4 Establishing the presence of blood vessels in the stroma of normal 
pancreata and KPC PDACs 
In the normal pancreas there are small to moderate numbers of well-formed blood 
vessels present between pancreatic acini, lobules and ducts. Within the stroma of 
KPC PDACs there are moderate numbers of poorly formed CD31 positive blood 
vessels (see Fig. 10). 
Figure 10: Microvessels within normal pancreata and KPC PDAC tissue 
Representative images of CD31 staining of endothelial cells of vessels within normal pancreata 
and KPC PDAC tissue (see arrows) (n=5-8). Arrow points to CD31 positive interlobular vessel. 
 
 
 
 
 
 
 
3.2.5 Establishing the presence of collagen within the stroma of normal 
pancreata and KPC PDACs 
Sirius red staining highlights, as expected, that there are moderate amounts of 
collagen present within the interlobular and periductal regions of the normal 
pancreas. It is also clear that there are large amounts of collagen present within 
the stroma of KPC PDACs surrounding the neoplastic epithelium (see Fig. 11). 
Figure 11: Stromal collagen in normal pancreata and KPC PDAC tissue 
Representative images of Sirius red staining (collagen and elastin) of normal pancreata and KPC 
PDAC tissue (n=5-8) 
 
 
 
 
 
 
 
 
Normal Pancreas – CD31 KPC PDAC– CD31 
Normal Pancreas – Sirius 
red 
KPC PDAC – Sirius red 
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3.2.6 Establishing the presence of tenascin C within the stroma of normal 
pancreata and KPC PDACs 
Due to the wide range of roles that tenascin C plays in the microenvironment of 
tumours and the importance, as shown by our lab, of tenascin C to tumour cell 
viability in vitro I next characterised the presence of tenascin C in the normal 
pancreas and in KPC PDACs. Through establishing and optimising an 
immunohistochemistry protocol for staining tenascin C in formalin fixed, paraffin 
embedded tissue I have shown that there is significant production of tenascin C in 
the stroma of KPC PDACs whereas there is limited production of tenascin C in the 
normal pancreas (see Fig. 12). 
Figure 12: Tenascin C presence within normal pancreata and KPC PDAC 
tissue 
Representative images showing tenascin C immunostaining in normal pancreata and KPC PDAC 
tissue. Notice the increased expression in the stroma of the PDAC tissue (n=5-8). 
 
 
 
 
 
 
 
3.3 Tenascin C in Pancreatic ductal adenocarcinoma 
In response to our earlier findings and the wide ranging roles tenascin C plays 
from tumourigenesis through to metastatic spread I next looked to further 
characterise tenascin C expression in the murine models of PDAC available in our 
lab and to determine the importance of tenascin C in human PDAC  
 
3.3.1 Mutant p53 causes an increase in intra-tumoural tenascin C expression 
compared with loss of p53 
It has previously been shown by Jen Morton that PDAC expressing mutant p53 as 
opposed to loss of p53 is capable of metastatic spread (Morton, Timpson et al. 
2010). Most work regarding the effects of p53 loss versus p53 mutation in PDAC 
has focussed on the changes to the tumour cells themselves. Due to the lack of 
metastasis in KPflC mice and the important role tenascin C plays in supporting 
Normal Pancreas – Tenascin C KPC PDAC – Tenascin C 
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metastasis in other epithelial cancers we looked to characterise the expression of 
tenascin C in both the KPC and the KPflC models. We have shown that loss of 
p53 does not lead to production of tenascin C whereas the presence of a gain-of-
function mutant p53 does (see Fig. 13). 
 
Figure 13: Presence of gain-of-function mutant p53 as opposed to loss of 
p53 causes an increase in the production of tenascin-C in tumours in mice. 
Shows representative X4 magnification images of tenascin-C stained p53-/- (KPflC) and p53R172H 
(KPC) tumours. There is markedly reduced tenascin-C expression in p53-/- tumours compared with 
p53R172H tumours (n=5-8). 
 
P53-/- P53R172H
 
 
3.3.2 Tenascin C is produced by the tumour stroma and not the tumour 
epithelium 
Having shown high expression of tenascin C within the stroma of KPC PDAC 
tumours (see Figs. 12 and 13) I next looked to further characterise the production 
of tenascin C utilising other models of PDAC. As discussed previously, work in our 
lab by Bryan Miller has shown that tenascin C production by the tumour epithelium 
itself is vital to cell viability in vitro. This finding is interesting given the stromal 
staining pattern of tenascin C that I have demonstrated in KPC PDAC tumours 
(see Fig. 12) and the generally accepted view that in epithelial cancers it is stromal 
cells that are responsible for the production of tenascin C. Due to these 
contradictory findings I next used orthotopic and subcutaneous human PDAC cell 
line xenograft models in nude mice to confirm the source of tenascin C in PDAC. 
Tenascin C immunohistochemistry is species specific (see Fig. 14), therefore by 
utilising this species specific staining it is clear that tenascin C is not directly 
produced by the tumour epithelium but is produced by stromal cells (see Fig. 15). I 
further confirmed the finding that the stroma is responsible for the production of 
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tenascin C in epithelial cancers using human colorectal carcinoma HCT 116 
tumour cell line subcutaneous xenografts (see Fig. 15).  
 
Figure 14: Tenascin-C antibodies provide species specific 
immunohistochemical staining of human and murine tissues. 
Shows representative X10 magnification images of tenascin-C stained mouse and human primary 
PDAC tissue with anti-mouse and anti-human tenascin-C antibodies. Note that there is no inter-
species cross-reactivity.  
 
Anti-human tenascin-C antibody on human tissue Anti-human tenascin-C antibody on murine tissue
Anti-mouse tenascin-C antibody on human tissue Anti-mouse tenascin-C antibody on murine tissue  
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Figure 15: Species specific Tenascin-C immunohistochemistry provides 
evidence for the stromal production of tenascin-C. 
a) Shows representative X10 magnification images of anti-human and anti-mouse anti-
tenascin-C stained human PDAC cell xenograft nude mouse models. Staining is only seen 
using the anti-mouse anti-tenascin-C staining therefore confirming tenascin-C production 
by the microenvironment and not the tumour cells themselves.  
b) Shows representative X10 magnification images of anti-human and anti-mouse anti-
tenascin-C staining in human colorectal carcinoma HCT 116 tumour cell line subcutaneous 
xenografts. 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
Anti-human tenascin-C antibody on human PDAC cell  
orthotopic mouse model
Anti-mouse tenascin-C antibody on human PDAC 
cell  orthotopic mouse model
Anti-mouse tenascin-C antibody on human PDAC 
cell  subcutaneous mouse model
Anti-human tenascin-C antibody on human PDAC 
cell  subcutaneous mouse model
 
Anti-human tenascin-C antibody on human HCT 116 
cell  l ine xenografts
Anti-mouse tenascin-C antibody on human HCT 
116 cell  l ine xenografts
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3.3.3 Tenascin C is produced by the tumour epithelium in the absence of 
stromal production 
Due to previous results in our lab and work by others showing that tenascin C 
production by the tumour epithelium is vital in establishment and survival of early 
breast cancer metastases (Oskarsson, Acharyya et al. 2011) I next looked to 
determine whether tenascin C could be produced by the tumour epithelium in vivo. 
I used subcutaneous allograft models of C57Bl6 KPC cell lines in syngeneic wild 
type (WT) and tenascin C knockout C57Bl6 mice to determine the importance of 
stromal tenascin C production. In this model allografted tumour cells are able to 
produce tenascin C but in the tenascin C knockout mice the stroma cannot. I have 
shown that in a WT recipient the stroma produces the tenascin C and the tumour 
epithelium does not stain, whereas in the tenascin C knockout recipient the stroma 
is unable to produce tenascin C and we see production of tenascin C by the 
tumour epithelium itself (see Fig. 16) 
 
Figure 16: Tenascin-C expression is predominantly stromal however it may 
also be expressed within the tumour epithelium. 
Shows representative X10 magnification images of tenascin-C stained C57BL/6 KPC cell line 
subcutaneous allografts in WT and tenascin-C -/- mice. Note the stromal expression in the wild 
type recipients and the tumoural expression in the tenascin-C -/- recipient.  
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
C57BL6 KPC in WT recipient C57BL6 KPC in tenascin-C -/- recipient
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3.4 Tenascin C and its importance in human PDAC 
Having shown the importance of tenascin C production in murine models of PDAC 
I next looked to confirm the production of tenascin C and determine its importance 
in human PDAC. 
 
3.4.1 Tenascin C is produced by the stroma of human PDAC and high levels 
of expression correlate significantly with survival    
Previous studies have found increased expression of tenascin C in acute and 
chronic pancreatitis, early PanIN lesions and PDAC in humans. Tenascin C 
expression has also been shown to correlate with differentiation of PDAC (Juuti, 
Nordling et al. 2004; Esposito, Penzel et al. 2006). Utilising a human PDAC tissue 
microarray I have shown that tenascin C is a significant stromal constituent and 
that expression significantly correlates with survival (Log-Rank p=0.043). Also 
patients expressing high levels of stromal tenascin C (n=59) had a median survival 
of 13.4 months whereas patients expressing low levels of tenascin C (n=59) had 
nearly a 50% increase in survival with a median survival of 22.6 months (see Fig. 
17). Immunohistochemical staining of this TMA also confirms that tenascin C 
production in these tumours is exclusively stromal and highly variable (see Fig. 
17). 
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Figure 17: Tenascin-C expression is significantly associated with survival in 
human PDAC.  
a) Kaplan-Meier survival analysis. There was a significant difference in survival between the 
survival of patients with tenascin-C expression above or below the median as determined 
by TMA histoscore (Log-Rank p=<0.043, n=118).  
b) Representative images of tenascin C immunohistochemistry in human PDAC TMA samples 
highlighting high and low stromal staining. 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
Human PDAC Tenascin C Low Human PDAC Tenascin C High 
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3.4.2 Tenascin C expression strongly correlates with hypoxia in human 
PDAC 
Previous studies have found increased production of tenascin C in states of 
hypoxia (Jones and Jones 2000). In my analysis of the human PDAC TMA there is 
a strong positive correlation between the transcription factor Hypoxia-inducible 
factor 1-alpha (Hif1α) and tenascin C levels in human disease (p=0.018, see Fig. 
18). 
 
3.4.3 Tenascin C expression strongly correlates with proliferation in human 
PDAC 
Tenascin C has been shown to promote both glioblastoma and breast carcinoma 
cell proliferation in vitro and in vivo (Chiquet-Ehrismann, Mackie et al. 1986; 
Huang, Chiquet-Ehrismann et al. 2001; Fukunaga-Kalabis, Martinez et al. 2010). 
In my analysis of the human PDAC TMA I have shown a significant correlation 
between tenascin C expression and proliferation in human PDAC (p=0.045 see 
Fig. 18). 
 
3.4.4 Tenascin C expression strongly correlates with integrin signalling in 
human PDAC 
Tenascin C is known to signal through integrins a large family of cell surface 
receptors. Tenascin C has been shown to signal through α2β1, αvβ3, α7β1, α8β1, 
α9β1, α5β3 and α5β6 integrins (Sriramarao, Mendler et al. 1993; Yokosaki, 
Palmer et al. 1994; Varnum-Finney, Venstrom et al. 1995; Yokosaki, Monis et al. 
1996). Interestingly in my analysis there is a strong correlation between tenascin C 
expression and αvβ6 integrin (see Fig. 18). 
 
3.4.5 Tenascin C expression is significantly associated with both tumour 
grade and vascular invasion in human PDAC 
Tenascin C is considered to have important roles in both epithelial to 
mesenchymal transition (EMT) and tumour cell migration (Deryugina, Bourdon et 
al. 1996; Nishio, Kawaguchi et al. 2005; De Wever, Nguyen et al. 2004; Maschler, 
Grunert et al. 2004; Dandachi, Hauser-Kronberger et al. 2001; Tanaka, Sumioka 
et al. 2010). I have shown that high expression of tenascin C significantly 
55 
 
correlates with tumour grade (p=0.049) and there is also a trend towards 
increased vascular invasion (p=0.052) (see Fig. 19).  
 
Figure 18: Tenascin C expression significantly correlates with proliferation, 
hypoxia and integrin αvβ6 in human PDAC TMA analysis. 
There is a strong positive correlation with Ki67 a proliferation marker, Hif1alpha which is induced in 
states of hypoxia and integrin αvβ6 (n=118). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19: Tenascin-C expression significantly correlates with tumour grade 
There is a positive correlation between tumour grade and tenascin-C expression with higher grade 
tumours producing more tenascin-C. There is also a trend towards tumours with higher tenascin-C 
expression exhibiting vascular invasion (n=118). Vascular invasion 1= invasion, 0= no invasion. 
 
 
 
 
 
 
 
 
 
 
 
 
*P=0.049 P=0.052 
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3.4.6 Tenascin C expression is significantly associated with lysyl-oxidase 
expression in human PDAC 
Finally we have shown in a human PDAC RNA microarray that there is a 
significant positive correlation between lysyl-oxidase expression and tenascin C 
expression (p<0.0001 see Fig. 20). 
 
Figure 20: Tenascin-C expression significantly correlates with lysyl-oxidase 
expression in human PDAC RNA microarray analysis. 
There is a significant positive correlation between lox expression and tenascin-C expression in 
human PDAC (spearmans rho correlation 0.61, p=<0.0001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Spearmans rho correlation 0.61, P < 0.0001 
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3.5 Evaluating stromal changes elicited by stromal targeting treatments in 
the KPC model of PDAC 
Having established reliable methods for quantifying cellular and non-cellular 
constituents of tumour stroma and establishing the presence and possible 
importance of tenascin C in PDAC we next looked to use these methods and 
staining protocols to evaluate stromal changes elicited in the KPC model by lysyl-
oxidase inhibition and CXCR2 inhibition. 
 
3.6 Lysyl-oxidase inhibition in the KPC model  
The role of lysyl-oxidase in tumour metastasis is well established, and it has been 
shown that inhibition of lysyl-oxidase reduces metastatic spread rather than 
reducing tumour initiation (Erler, Bennewith et al. 2006). In light of recent work 
showing that tumour stroma inhibits penetration of gemcitabine into PDAC (Olive, 
Jacobetz et al. 2009), and given the role that lysyl-oxidase plays in cross-linking 
collagen, we next determined the effect of lysyl-oxidase inhibition alone and in 
combination with gemcitabine on both metastatic spread and on the primary 
tumour itself. 
 
3.6.1 Lysyl-oxidase inhibition delays tumorigenesis and stops metastasis 
Work by Jen Morten and Bryan Miller in our lab has shown that KPC mice treated  
with LOX-Ab show a significant increase in survival, furthermore mice treated with 
the combination of gemcitabine and LOX-Ab had a further increase in survival, 
with a median survival of 226 days (Log-Rank p<0.002) (see Fig. 21). Importantly 
in the groups of mice treated with LOX-Ab alone or LOX-Ab/gemcitabine 
combination there were reduced instances of metastasis (0/8 and 2/13 
respectively, compared with 9/11 treated with gemcitabine alone).  
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Figure 21: LOX inhibition significantly delays tumorigenesis and stops 
metastasis in KPC mice.  
 
Kaplan-Meier survival analysis. There was a significant difference in survival between the LoxAB 
treated and the LoxAB/Gemcitabine treated cohorts (Log-Rank p=<0.002). There was also reduced 
incidence of metastasis noted in the Lox-Ab and Lox-Ab/Gemcitabine treatment cohorts. 
(Results and figure courtesy of Jen Morton) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.2 Characterising the effects of Lox-Ab and gemcitabine treatment on the 
KPC tumour epithelium and microenvironment 
Having shown the significant effect of lysyl-oxidase inhibition on survival, alone 
and in combination with gemcitabine, it was next important to characterise the 
effects treatment was having on both the tumour epithelium and the tumour 
microenvironment 
 
3.6.3 Lysyl-oxidase inhibition significantly reduces the tumoural expression 
of tenascin C in KPC mice 
Considering the previously highlighted significant correlation between lysyl-
oxidase and tenascin C expression in human PDAC we next looked to determine 
the effects of lysyl-oxidase inhibition on the expression of tenascin C in the KPC 
model of PDAC. Additionally tenascin C is produced in response to a wide variety 
of cellular signals such as hypoxia and in response to mechanical strain (Jones 
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and Jones 2000) therefore we looked to quantify tumoural tenascin C expression 
in Lox-Ab treated mice. In the context of lysyl-oxidase inhibition elicited by Lox-Ab 
treatment there is markedly decreased tenascin C expression in tumours. We 
have also shown that gemcitabine treatment induces increased stromal tenascin C 
expression when compared with vehicle treated mice. It is also clear that Lox-Ab 
treatment is able to inhibit the increased stromal expression of tenascin C in 
response to gemcitabine (see Fig. 22). Interestingly in the treatment KPC tumours 
treated with the combination of gemcitabine and lysyl-oxidase inhibition we also 
begin to see increased expression by the tumour epithelium itself as opposed to 
the increased stromal expression noted in vehicle or gemcitabine alone treated 
KPC mice (see Fig. 23). 
 
Figure 22: Lysyl-oxidase inhibition significantly reduces the expression of 
tenascin-C in KPC tumours. 
Representative x4 magnification images of tenascin-C staining of tumour  tissues. 
Lox inhibition markedly decreases the expression of tenascin-C in Lox treated KPC tumours. 
Gemcitabine is also noted to markedly increase expression of tenascin-C, a change that is not 
noted when used in conjunction with Lox inhibition. 
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Figure 23: Tenascin-C expression is predominantly stromal however it may 
also be expressed within the tumour epithelium. 
Shows representative X20 magnification images of tenascin-C stained gemcitabine treated and 
lox/gemcitabine treated KPC tumours. Note the stromal staining pattern in the gemcitabine treated 
tumour compared to the mild cytoplasmic staining of tumour cells in the Lox/gemcitabine treated 
tumour. 
 
3.6.4 Lysyl-oxidase inhibition significantly increases intra-tumoural 
microvessel density 
Given the decrease in the stromal tenascin C expression caused by Lox-Ab 
treatment we looked to determine whether there was an effect on the tumour 
microvasculature. Amy Au in our lab has shown that there is a significant increase 
in intra-tumoural microvasculature in Lox-Ab and Lox-AB/gemcitabine combination 
treatment groups compared to vehicle treated and gemcitabine alone (data not 
shown).  
 
3.6.5 Lysyl-oxidase inhibition in conjunction with gemcitabine treatment 
significantly increases intra-tumoural necrosis but has no significant effect 
on apoptosis 
Work done in the lab by Jen Morten in KPC mice had previously shown that there 
was no significant change in tumour epithelium proliferation rate as assessed by 
Ki67 immunostaining and quantification. Given that there was no change in tumour 
proliferation I next characterised the changes in tumour cell survival by 
quantification of apoptosis and necrosis. Through quantification of intra-tumoural 
necrosis I have shown a significant increase in intra-tumoural necrosis in the Lox-
Ab/gemcitabine combination treatment group compared with gemcitabine alone 
and vehicle treated mice (p=0.034 and 0.022 respectively, see Fig. 24). There is 
also a trend towards increased necrosis in the Lox-AB/gemcitabine combination 
treatment group compared to lysyl-oxidase inhibition alone (p=0.101 see Fig. 24). 
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Through quantification of apoptosis (positive immunostaining for cleaved caspase-
3) I have shown that there is no significant alteration in apoptosis in the tumour 
epithelium (see Fig. 25). These findings are interesting given the increased intra-
tumoural microvessel density previously noted in the Lox-Ab treatment groups. 
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Figure 24: Lysyl-oxidase inhibition in combination with gemcitabine 
treatment significantly increases intra-tumoural necrosis in KPC mice. 
 
a) Shows representative X4 magnification images of PDAC necrosis in Lox treatment cohorts 
b) Quantification of necrosis in Lox treatment cohorts. There was a significant difference in necrosis 
between the LoxAB/Gemcitabine treatment cohort and vehicle treated and gemcitabine alone 
treated cohorts (Mann-Whitney U test, p=0.022 and 0.034 respectively, group size n≥3) and a 
trend towards increased necrosis over Lox treatment alone. 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
 
 
 
 
 
 
 
 
 
 
 
LoxAb treated KPC tumour Vehicle treated KPC tumour 
Gemcitabine treated KPC tumour LoxAb+Gem treated KPC tumour 
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Figure 25: Lysyl-oxidase inhibition has no significant effect on apoptosis in 
PDAC in KPC mice 
Quantification of apoptosis (cleaved Caspase-3 positive cells) in Lox treatment cohorts. There was 
no significant difference in apoptosis between treatments (Mann-Whitney U test, group size n≥3). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.6.6 Lysyl-oxidase inhibition in combination with gemcitabine significantly 
increases intra-tumoural leukocyte infiltration 
Utilising characteristic morphology and F4/80 staining I have quantified the intra-
tumoural infiltrate of neutrophils and macrophages respectively. I have shown a 
significant increase in intra-tumoural neutrophils in the Lox-Ab/gemcitabine 
combination treatment group compared with gemcitabine alone and vehicle 
treated mice and a trend toward increased intratumoural neutrophils compared to 
lysyl-oxidase inhibition alone (p=0.027, 0.027 and 0.117 respectively) (see Fig. 
26). There is also a significant increase in intra-tumoural infiltration of 
macrophages in the Lox-Ab/gemcitabine combination treatment group compared 
to the vehicle treated, Lox-AB alone and gemcitabine alone treatment groups 
(p=0.014, 0.004, 0.023 respectively) (see Fig. 27). 
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Figure 26: Lysyl-oxidase inhibition in combination with gemcitabine 
treatment significantly increases intra-tumoural neutrophil infiltrates in KPC 
mice. 
a) Shows a representative image X40 magnification of neutrophil appearance on standard H&E 
stained tumour section. Inset note the characteristic nuclear shape and eosinophilic cytoplasm. 
b) Quantification of intra-tumoural neutrophil numbers in Lox treatment cohorts. There was a 
significant difference in intra-tumoural neutrophil numbers between the LoxAB/Gemcitabine 
treatment cohort and vehicle treated and gemcitabine alone treated cohorts (Mann-Whitney U 
test, p=0.027 and 0.027 respectively, group size n≥3) and a trend to increased intra-tumoural 
neutrophil infiltrate over Lox treatment alone. 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 27: Lysyl-oxidase inhibition in combination with gemcitabine 
treatment significantly increases intra-tumoural macrophage infiltration in 
KPC mice. 
a) Shows representative X40 magnification F4/80 stained images in Lox treatment cohorts. 
b) Quantification of intra-tumoural macrophage infiltration in Lox treatment cohorts by pixel count 
analysis of F4/80 stained tissues. There was a significant difference in intra-tumoural macrophage 
infiltration between the LoxAB/Gemcitabine treatment cohort and vehicle treated, LoxAB alone 
and gemcitabine alone treated cohorts (Mann-Whitney U test, p=0.014, p=0.004 and 0.023 
respectively, group size n≥3). 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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3.7 CXCR2 inhibition in the KPC model 
CXCR2 signalling has increasingly been implicated in cancer and inflammatory 
conditions (Matsuo, Ochi et al. 2009; Li, King et al. 2011; Gabellini, Trisciuoglio et 
al. 2009) and it is well known that inflammation may in part lead to the 
development of PDAC (Duell, Casella et al. 2006). CXCR2 is expressed on a wide 
variety of cell types including inflammatory cells, tumour epithelial cells and other 
stromal cells such as endothelial cells. Therefore we looked to determine the 
effects of CXCR2 inhibition alone and in combination with gemcitabine treatment 
on the both the tumour epithelium and the tumour microenvironment. 
 
3.7.1 CXCR2 inhibition significantly increases survival in KPC mice 
Work undertaken by Colin Steele in our lab has shown that pepducin treatment 
(inhibition of CXCR2) significantly increases survival in KPC mice (Log-Rank 
p=<0.002) (see Fig. 28). Furthermore it has been shown that combination of 
pepducin treatment with gemcitabine treatment also reduces incidence of 
metastasis. 
 
Figure 28: CXCR2 inhibition significantly increases survival in KPC mice.  
 
Kaplan-Meier survival analysis. There was a significant difference in survival between the pepducin 
treated and the vehicle treated cohorts (Log-Rank p=<0.002, group size n=20). There was also 
reduced incidence of metastasis noted in the pepducin/gemcitabine treatment cohort. 
(Results and figure courtesy of Colin Steele). 
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3.7.2 CXCR2 inhibition significantly increases intra-tumoural necrosis but 
has no effect on apoptosis 
Due to the increase in survival we first characterised the effects of CXCR2 
inhibition on the tumour epithelium itself. Work done in the lab by Colin Steele had 
previously highlighted that there was no significant change in cell proliferation rate 
as assessed by Ki67 immunostaining and quantification. Due to the lack of effect 
on proliferation I next characterised the changes in tumour cell viability by 
quantifying levels of apoptosis and necrosis. Quantification of intra-tumoural 
necrosis shows that pepducin treatment significantly increases intra-tumoural 
necrosis when compared to vehicle treatment or gemcitabine treatment alone 
(p=0.007 and 0.034 respectively). This increase in necrosis compared to vehicle 
was not seen in the gemcitabine alone treatment group and combination treatment 
with gemcitabine does not further increase intra-tumoural necrosis (see Fig. 29). 
Quantification of apoptotic tumour epithelium showed no significant difference 
between treatment groups (see Fig. 30). 
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Figure 29: CXCR2 inhibition significantly increases necrosis in KPC 
tumours. 
a) Shows representative X4 magnification images of PDAC necrosis in pepducin treatment cohorts 
b) Quantification of necrosis in pepducin treatment cohorts. There was a significant difference in 
necrosis between pepducin and pepducin/gemcitabine treatment compared with vehicle 
treatment (Mann-Whitney U test, p=0.007 and p=0.009 respectively, group size n≥3). There was a 
significant increase in necrosis in pepducin treatment alone compared to gemcitabine treatment 
alone (Mann-Whitney U test, p=0.034, group size n≥3) and there was a trend towards increased 
necrosis in the pepducin/gemcitabine treatment compared to the gemcitabine alone. 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 30: CXCR2 inhibition has no effect on apoptosis in KPC tumours. 
Quantification of apoptosis (cleaved caspase-3 positive cells) in pepducin treatment cohorts.   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.7.3 CXCR2 inhibition significantly reduces intra-tumoural microvessel 
density 
Given the increase in intra-tumoural necrosis produced by pepducin alone, the 
inability of gemcitabine to further increase necrosis when given in combination with 
pepducin and the importance of CXCR2 signalling in angiogenesis (Li, Cheng et 
al. 2011) I next quantified intra-tumoural microvessel density. Pepducin treatment 
(CXCR2 inhibition) significantly decreases intra-tumoural microvessel density 
when compared with vehicle treatment (p=0.025) (see Fig. 31). This change was 
consistent and unaffected by combination of pepducin with gemcitabine treatment 
(p=0.025) (see Fig. 31).   
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Figure 31: CXCR2 inhibition significantly decreases vessel count in KPC 
tumours. 
a) Shows a representative X20 magnification image of PDAC CD31 immunostaining in tumour tissue. 
b) Quantification of vessel counts in pepducin treatment cohorts. There was a significant difference in 
vessel counts between pepducin and pepducin/gemcitabine treatment compared with vehicle 
treatment (Mann-Whitney U test, p=0.025 and p=0.025 respectively, group size n≥3) and 
gemcitabine alone (Mann-Whitney U test, p=0.027 and p=0.050 respectively group size n≥3). 
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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3.7.4 CXCR2 inhibition increases intra-tumoural expression of tenascin C in 
KPC mice 
As tenascin C is expressed in situations of hypoxia, I next characterised the 
change elicited in tenacin C expression in response to CXCR2 inhibition. I stained 
for tenascin C which shows that CXCR2 inhibition leads to increased tenascin C 
production within the stroma of KPC tumours (see Fig. 32). 
 
Figure 32: CXCR2 inhibition increases the expression of tenascin-C in KPC 
tumours. 
Representative x10 magnification images of tenascin-C staining of pepducin treatment cohorts. 
CXCR2 inhibition markedly increases the expression of tenascin-C in pepducin treated KPC 
tumours. Gemcitabine treatment is also noted to markedly increase expression of tenascin-C. 
Pepducin and gemcitabine when given in combination have an additive effect on the increase in 
tenascin-C expression (group size n=5). 
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3.7.5 CXCR2 inhibition reduces intra-tumoural leukocyte infiltration in KPC 
mice 
Previous studies have shown a significant reduction in neutrophil and macrophage 
numbers in response to CXCR2 inhibition (Ijichi, Chytil et al. 2011). In agreement 
with this finding I have shown that in pepducin treated KPC mice there is a non-
significant trend towards decreased numbers of intra-tumoural neutrophils and 
macrophages (see Figs. 33, 34 and 35). 
 
Figure 33: CXCR2 inhibition decreases neutrophil tumour infiltration in KPC 
mice (Haematoxylin and Eosin stain). 
Quantification of neutrophils (haematoxylin and eosin stain) in pepducin treatment cohort. There 
was a non-significant trend towards decreased neutrophil numbers in pepducin treated tumours. 
This reduction was not seen when combination treatment with gemcitabine was given (Mann-
Whitney U test, group size n≥3).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.102
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Figure 34: CXCR2 inhibition decreases neutrophil tumour infiltration in KPC 
mice (MPO immunostaining). 
 
a) Shows a representative X40 magnification image of PDAC myeloperoxidase (MPO) immunostaining 
in tumour tissue. 
b) Quantification of neutrophils (MPO positive cells) in pepducin treatment cohorts. There was a non-
significant trend towards decreased neutrophil numbers in pepducin treated tumours. This 
reduction was not seen when combination treatment with gemcitabine was given (Mann-Whitney 
U test, group size n≥3).  
 
a) 
 
 
 
 
 
 
 
 
 
 
 
 
 
b) 
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Figure 35: CXCR2 inhibition decreases macrophage tumour infiltration in 
KPC mice. 
a) Shows representative X40 magnification images of F4/80 stained vehicle treated and pepducin 
treated tumour tissue. 
b) Quantification of macrophages (F4/80 staining by pixel count analysis) in pepducin treatment 
cohorts. There was a non-significant trend towards decreased macrophage numbers in pepducin 
treated tumours. This reduction was not seen when combination treatment with gemcitabine was 
given (Mann-Whitney U test, group size n≥3).  
 
a) 
 
 
 
 
 
 
 
b) 
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3.7.6 CXCR2 inhibition reduces intra-tumoural collagen and elastin and intra-
tumoural myofibroblast number in KPC mice 
CXCR2 expression by neutrophils is widely appreciated, however other cell types 
including fibroblasts have also been shown to express CXCR2 (Ijichi, Chytil et al. 
2011; Marotte, Ruth et al. 2010). I quantified the levels of collagen and elastin in 
tumours utilising Sirius red staining and through immunohistochemical staining for 
alpha-SMA evaluated the numbers of myofibroblasts in treatment groups. CXCR2 
inhibition caused a significant decrease in the amounts of intra-tumoural collagen 
and elastin (p=0.021) (see Fig. 36) and a decrease in the number of alpha-SMA 
positive cells (see Fig. 37). 
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Figure 36: CXCR2 inhibition decreases collagen and elastin in KPC tumours. 
a) Shows representative X20 magnification images of Sirius Red stained vehicle treated and pepducin 
treated tumour tissue. 
b) Quantification of collagen and elastin (Sirius red staining by pixel count analysis) in pepducin 
treatment cohorts. There was a significant decrease in collagen and elastin in pepducin treated 
tumours (Mann-Whitney U test, p=0.021, group size n≥3). This reduction was not seen when 
combination treatment with gemcitabine was given.  
 
 
a) 
 
 
 
 
 
 
 
b) 
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Figure 37: CXCR2 inhibition decreases myofibroblast numbers in KPC 
tuours. 
Shows representative X20 magnification images of alphaSMA stained vehicle treated and pepducin 
treated tumour tissue. 
 
 
 
 
 
 
 
 
 
3.8 Constitutive CXCR2 knock out in the KPC model 
Our lab has shown that inhibition of CXCR2 by pepducin has significant effects on 
overall survival in the KPC model of PDAC (pharmacological deletion) as well as 
having profound effects on the tumour epithelium and the tumour 
microenvironment. Work by Colin Steele in the lab is on-going to characterise the 
effect of constitutive knock out of the CXCR2 gene in the KPC model using a 
genetic model and the following are early results highlighting the changes seen in 
the microenvironment.  
 
3.8.1 Constitutive CXCR2 knock out reduces intra-tumoural neutrophil 
infiltration in KPC mice 
CXCR2 signalling is vital for neutrophil chemotaxis to sites of inflammation. I have 
shown that constitutive CXCR2 knock out significantly reduces intratumoural 
neutrophil infiltration in KPC mice treated with gemcitabine and a there is a trend 
towards decreased neutrophil numbers in CXCR2 knock out KPC mice for which 
we currently have small numbers (p=0.034, p=0.083 respectively) (see Fig. 38). 
This trend is also seen with pepducin inhibition of CXCR2 signalling but is found to 
be a significant finding in the context of a constitutive CXCR2 knock out. 
 
 
 
 
 
Vehicle treated KPC tumour Pepducin treated KPC tumour
 
78 
 
Figure 38: CXCR2 KO decreases neutrophil tumour infiltration in KPC mice. 
Neutrophil quantification (MPO positive cells) in tumours in CXCR2 KO mice and mice expressing 
functional CXCR2 (group size n=2, ongoing cohort). 
 
 
 
 
 
 
 
 
 
 
 
 
 
3.8.2 Constitutive CXCR2 knock out does not alter intra-tumoural 
microvessel density in KPC mice 
I have previously shown that inhibition of CXCR2 signalling with pepducin 
treatment significantly reduces intra-tumoural microvessel density in KPC mice. I 
therefore looked to characterise changes to the tumour vasculature in the context 
of constitutive knock out of CXCR2. In contrast to pepducin mediated CXCR2 
inhibition, constitutive knock out of CXCR2 does not have a significant effect on 
the intra-tumoural microvessel density (see Fig. 39). 
 
 
 
 
 
 
 
 
 
 
 
 
P=0.083
P=0.034
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Figure 39: CXCR2 KO has no effect on vessel count in KPC tumours. 
There is no change in vessel count between tumours in CXCR2 knockout mice and mice 
expressing CXCR2. 
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3.8.3 Constitutive CXCR2 knock out does not alter intra-tumoural expression 
of tenascin-C in KPC mice 
Having shown that constitutive knockout of CXCR2 has no effect on intra-tumoural 
microvessel density I next demonstrated that constitutive knock out of CXCR2 also 
has no effect on levels of intra-tumoural tenascin C (see Fig. 40). 
 
Figure 40: CXCR2 KO has no effect on tenascin-C expression in KPC 
tumours. 
There is no change in tenascin-C production between CXCR2-/- tumours and CXCR2 expressing 
tumours (group size n≥2). 
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Chapter 4 
Discussion 
4.1 Pancreatic ductal carcinoma and the importance of its microenvironment 
In this thesis I have established robust methods of stromal characterisation and 
novel immunohistochemistry protocols. I have subsequently applied these 
methods and characterised the stroma of the KPC model of PDAC and compared 
this with the normal pancreas as well as determining the stromal changes caused 
by specific targeted therapies. In the UK pancreatic cancer is the fifth highest 
cause of death by cancer with a median survival post-diagnosis of only 6 months. 
This situation has changed little in the past few decades with median survival 
barely altering between 1971 and 2007. To date therapies that target specific 
molecular alterations within the cancer cells themselves, which have been 
successful in other tumour types, have not been successful in treating PDAC 
(Jang and Atkins 2013; Yauch and Settleman 2012). In response to the lack of 
success in directly targeting the tumour epithelial cells, increasing interest has 
been given to targeting the tumour microenvironment, a characteristic for which 
PDAC is well known (Feig, Gopinathan et al. 2012). In our lab a number of 
approaches have been taken to target the tumour microenvironment and these 
have greatly increased survival in mouse models of PDAC. In order to begin to 
further understand the mechanisms by which these approaches affect the mouse 
tumours it was first vital to establish robust methods for stromal characterisation. 
 
4.2 Establishing robust methods for stromal characterisation 
With the increasing interest in stromal targeting in cancer therapy, particularly for 
pancreatic cancer, there have been increasing numbers of publications evaluating 
the effects of different stromal targeting therapies (Bramhall, Rosemurgy et al. 
2001; Provenzano, Cuevas et al. 2012; Olive, Jacobetz et al. 2009; Jacobetz, 
Chan et al. 2013). Unfortunately the methods used in these publications vary 
greatly in their fastidiousness. We argued that it should be possible to develop a 
methodological approach that is less open to variation due to the subjectivity that 
affects these other scoring methods. Through evaluating a broad range of cellular 
and non-cellular stromal constituents and scoring all non-overlapping tumour FOV 
whilst simultaneously evaluating the running mean and standard error in each 
example I have established a more robust method for stromal characterisation. I 
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have shown that reliable estimations of stromal constituents may be obtained by 
scoring a minimum of 30 FOV at X20 magnification or 60 FOV at X40 
magnification. This method, although more time consuming, is achievable and 
provides a minimum number of fields that must be evaluated in order to produce a 
representative average for any stromal constituent. I aimed to establish improved 
methods for histological analysis of stromal constituents and in so doing have 
increased the reliability of this method in stromal evaluation. Importantly however 
this approach will benefit from being run in tandem where possible with flow 
cytometry for cellular constituents and Western-blot and/or qPCR analysis where 
appropriate for other non-cellular components. Alone, and importantly in 
conjunction with these other methods of evaluation, the more robust method for 
histological assessment and quantification I have developed and used for all my 
analyses will lead to greater accuracy and more meaningful results when 
characterising stromal changes in models of cancer.  
 
4.3 Stromal characterisation of the KPC model of PDAC 
Through our initial analyses we have shown that the stromal constituents of PDAC 
differ greatly in composition and proportion from the stroma of the normal 
pancreas. We have shown that there is a prominent increase in the amount of 
stroma with a dramatic increase in the amount of collagen and the number of 
activated myofibroblasts. We have shown that there is an increase in the number 
of inflammatory cells within the stroma of PDAC compared to the normal 
pancreas. We have also shown that there are significant changes in the tumour 
epithelium with moderate to marked amounts of necrosis compared with the 
parenchyma of the normal pancreas. 
 
4.3.1 Characterisation of myofibroblasts and pancreatic stellate cell numbers 
in PDAC 
Existing literature regarding PDAC refers extensively to the significant contribution 
that pancreatic stellate cells make to the population of activated myofibroblasts in 
the stroma (Apte, Park et al. 2004). In this literature cellular alphaSMA positivity 
has been used to label and quantify pancreatic stellate cells. As discussed 
previously alphaSMA is not a specific marker for pancreatic stellate cells and any 
activated fibroblast from any origin as well as other cells such as pericytes will 
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stain for alphaSMA. The lack of specificity of alphaSMA as a marker for pancreatic 
stellate cells led us to investigate the utility of GFAP as a more specific marker for 
pancreatic stellate cells in PDAC. Pancreatic stellate cells are considered to be of 
neural crest origin and as such produce the intermediate filament GFAP. 
Unfortunately the characterisation of pancreatic stellate cells has been limited by 
the ability to isolate and study these cells in culture (Apte, Haber et al. 1998; Apte, 
Park et al. 2004; Wehr, Furth et al. 2011). One limitation is the fact that pancreatic 
stellate cells growing in an in vitro setting immediately become activated. 
Additionally the availability of specific markers which may be used to specifically 
isolate pancreatic stellate cells is also limited. GFAP is generally considered to be 
produced by quiescent pancreatic stellate cells however the literature surrounding 
activated pancreatic stellate cells is unfortunately less clear. I have shown that 
GFAP immunohistochemistry stains a small population of cells within the normal 
pancreas which are situated in the periacinar region as would be expected for 
pancreatic stellate cells. I have also shown that there is a small population of 
GFAP positive cells present in both human and KPC PDACs. Importantly however, 
the number of GFAP positive cells does not match the number of alphaSMA 
positive myofibroblasts in KPC tumours and this discrepancy is large in scale with 
the number of alphaSMA positive cells vastly exceeding the small number of 
GFAP positive cells present (see Fig. 9). This discrepancy may be explained by 
the fact that there are potentially multiple sources capable of contributing to the 
myofibroblast population in the KPC tumours. This is certainly a possibility with 
pericytes, fibrocytes, endothelial cells (through the process of endothelial to 
mesenchymal transition) and even epithelial cells (through epithelial to 
mesechymal transition) all capable of contributing to the cell population with a 
spindloid morphology and alphaSMA positivity (Kalluri and Neilson. 2003; van 
Meeteren and ten Dijke. 2012). It is also possible that although GFAP is a useful 
marker of quiescent stellate cells it may be unreliable as a marker once the cells 
have undergone activation and the associated cellular changes undertaken when 
becoming myofibroblasts. Indeed the morphology of the few GFAP positive cells 
within our KPC tumours is that of quiescent stellate cells (round and plump) and it 
is also possible that GFAP expression upon activation is dramatically reduced.  
Further evaluation of the origin of the myofibroblast population in pancreatic 
cancer will be required, utilising better and more specific markers, in order to 
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elucidate the true role played by pancreatic stellate cells in PDAC. The possibility 
of performing lineage tracing experiments utilising GFAP driven expression of Cre 
recombinase and LSL-GFP under the alphaSMA promoter is under investigation in 
our lab and may provide useful and vital insight into this population of cells.  If 
confirmed, the finding that the proportion of pancreatic stellate cell derived 
myofibroblasts is small does not rule out the possibility that these cells are central 
to guiding the formation and ongoing remodelling of the tumour stroma. However it 
would seem prudent, until further characterised, to designate these cells 
generically as activated myofibroblasts rather than implying they are derived from 
pancreatic stellate cells.  
 
4.3.2 Stromal characterisation highlights the increased levels of tenascin C 
in KPC stroma  
Having characterised the constituents of the stroma within the KPC model of 
PDAC I next looked to determine levels and location of expression of tenascin C. 
Tenascin C has been previously shown to be produced in human PDAC however 
tenascin C production has not been previously reported in the KPC model of 
PDAC (Juuti, Nordling et al. 2004). I have developed and optimised an 
immunohistochemistry protocol for staining formalin fixed, paraffin embedded 
tissues for tenascin C which has shown that tenascin C is not produced in the 
normal pancreas but is present in the stroma of KPC-driven PDAC. 
 
4.4 Tenascin C in PDAC 
Tenascin C expression has been detected with increased frequency in the 
progression from early PanIN lesions through to PDAC (Esposito, Penzel et al. 
2006). As a component of the extracellular matrix with significant effects on tumour 
cell behaviour and viability I looked to further characterise the expression of 
tenascin C in human PDAC and in our murine models of PDAC. I also looked to 
characterise changes in tenascin C expression in response to stromal targeted 
therapies. 
Having established and optimised an immunohistochemistry protocol for staining 
tenascin C in formalin fixed, paraffin embedded tissue I was able to show that 
there is significant stromal production of tenascin C in the KPC model of PDAC. 
85 
 
This showed, as we suspected, that the KPC model of PDAC mirrors the stromal 
production of tenascin C as seen in the human disease. This finding further 
highlights the usefulness of the KPC model for studying the complex stroma found 
within these tumours. 
Utilising the immunohistochemistry protocol for tenascin C I was next able to show 
that tenascin C expression is higher in tumours with mutated p53 (KPC) compared 
to those which have lost p53 (KPflC). It has previously been shown by Jennifer 
Morton in our lab that the presence of mutant p53 as opposed to loss of p53 
results in the capacity for tumour cells to metastasise. Interestingly the majority of 
the subsequent work focussing on the effects of mutant gain-of-function p53 has 
focussed on the changes resulting in the tumour epithelium yet here we have 
shown a clear difference between the stromal constituents of these tumours. This 
interesting finding perhaps provides a mechanism by which gain-of-function p53 
mutations may alter the stromal microenvironment and, given the established role 
of tenascin C in metastasis, increase their metastatic ability in a non-tumour cell 
autonomous way.  
Using human PDAC cell line xenografts and species specific tenascin C staining, I 
have shown that tenascin C production in PDAC is undertaken by stromal cells as 
opposed to the tumour cells themselves. Importantly however, using KPC cell line 
allografts in tenascin C knockout mice I have shown that the tumour epithelium 
itself will produce tenascin C in the absence of stromal production, therefore 
potentially highlighting a significant requirement for tenascin C expression within 
PDAC. This finding is consistent with the findings of Oskarsen et al. in which they 
found that production of tenascin C by metastatic mammary epithelial cells was 
vital for tumour cell survival until stromal production in the metastatic niche had 
reached adequate levels at 21 days (Oskarsson, Acharyya et al. 2011). 
Interestingly where the combination of Lox-Ab and gemcitabine is given eliciting 
dramatically reduced stromal tenascin the tumour epithelium itself appears to 
upregulate production of tenascin C. These results all confirm the importance of 
tenascin C to PDAC epithelial cells which was initially highlighted by the work of 
Bryan Miller in our lab showing that the production of tenascin C by PDAC cell 
lines in vitro is vital to cell viability. In this context it would seem that tenascin C is 
upregulated in vitro by cells growing in the absence of stromal cells and 
86 
 
associated ECM as a “stress response” due to a lack of supportive stromal 
signalling including altered mechanotransduction and other cytokine pathways. 
Taken together these findings all point to the vital role tenascin C plays in both the 
primary tumour and the metastatic niche and as such when the stroma is not 
capable of producing tenascin C the epithelium will produce tenascin C itself. 
In the KPC mouse model of PDAC I have shown that treatment with gemcitabine 
triggers a significant increase in the expression of tenascin C. It is interesting to 
speculate that this may be a specific response leading to resistance to 
gemcitabine therapy as has been shown previously (Gong, Lv et al. 2010) or a 
general tumour stress response.  
I have shown that lysyl-oxidase inhibition impairs the ability of the tumours to 
express stromal tenascin C. This impaired tenascin C expression may in part 
explain the loss of tumour viability through lack of supportive tumour-ECM 
signalling or it is tempting to speculate that the lack of protective annexin II 
signalling triggered by tenascin C possibly leads to a specific increase in 
susceptibility to gemcitabine therapy as demonstrated by Gong et al. (Gong, Lv et 
al. 2010). It is equally possible that the lack of tenascin C production is simply a 
result of reduced tissue hypoxia, due to the increase in vascular supply that we 
have demonstrated in response to lysyl-oxidase inhibition. If this is the case then it 
is possible that the tumoural responses noted are due to increased gemcitabine 
delivery and perhaps increased chemosensitivity due to increased vascular supply 
which in turn will reduce hypoxia. 
Interestingly in contrast to the changes elicited by lysyl-oxidase inhibition I have 
also shown that tenascin C is upregulated in KPC PDAC tumours in response to 
CXCR2 inhibition with pepducin. This increase is likely a stress response which 
may be a direct result of increased tissue hypoxia due to decreased intra-tumoural 
microvessel density. It is interesting to speculate that this increase in tenascin C is 
due to increased tissue hypoxia especially given the reduction in tenascin C 
production noted in the context of lysyl-oxidase inhibition which increases vascular 
supply. Importantly lysyl-oxidase inhibition leads to increased intratumoural 
microvessel density, increased necrosis, a reduction in tenascin C expression and 
an increase in infiltrating leukocytes whereas CXCR2 inhibition leads to decreased 
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intratumoural microvessel density, increased necrosis, increased tenascin C 
expression but no increase in infiltrating leukocyte numbers. Both however lead to 
increased survival and neither result in increased incidence of metastasis which is 
important especially in the context of CXCR2 inhibition given previous findings that 
hypoxia appears to be associated with increased metastasis in pancreatic ductal 
adenocarcinoma (Matsuo, Ding et al. 2013). The reduced incidence of metastasis 
in this example of increased hypoxia is in agreement with other findings in our lab 
where VEGF inhibition had no effect on metastasis in the KPC model. Importantly 
in the context of both lysl-oxidase inhibition and CXCR2 inhibition the presence or 
absence of hypoxia will need to be confirmed utilising methods such as 
pimonidazole or GLUT-1 staining. Tenascin C production however is also triggered 
by alterations in tissue stiffness (Jones and Jones 2000) so it is also possible that 
the increased production of tenascin C noted upon CXCR2 inhibition could be the 
result of altered ECM composition and architecture as highlighted by the reduction 
in collagen and elastin and also the reduction in myofibroblast numbers in treated 
tumours. Given preliminary findings in the setting of PDAC in a genetic model of 
CXCR2 deletion (CXCR2 -/-) where there is no decrease in tumour vasculature 
and concurrently there is also no increase in tenascin C production it seems 
plausible that the increased tenascin C production in response to pepducin 
treatment is likely due to hypoxia. This finding is consistent with my finding that the 
production of tenascin C in the human PDAC TMA strongly correlates with levels 
of HIF-1alpha.   
In agreement with others I have shown that tenascin C significantly correlates with 
differentiation in human PDAC (Juuti, Nordling et al. 2004). Additionally our data, 
to the best of our knowledge, show for the first time a significant correlation 
between high tenascin C expression and decreased survival in human PDAC 
patients (see Fig. 17). In my analysis of the tenascin C levels in the human TMA I 
have also shown that there is a significant positive correlation between tenascin C 
levels and tumour cell proliferation, tumour grade and there is also a trend towards 
a positive correlation between tenascin C expression and vascular invasion. As 
stated previously this analysis of the human PDAC TMA has also confirmed the 
positive correlation between hypoxia and tenascin C expression. These findings, 
which would benefit from confirmation in whole tumour sections in addition to this 
TMA, may in part explain the reasons for decreased survival in patients with high 
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levels of tenascin-C expression and again highlight the important role tenascin C 
plays in both the primary PDAC tumours and in the metastatic process. 
Interestingly in agreement with others, analysis of tenascin C production in the 
human PDAC TMA highlights a significant positive correlation between integrin 
signalling and tenascin C (Sriramarao, Mendler et al. 1993; Yokosaki, Palmer et al. 
1994; Varnum-Finney, Venstrom et al. 1995; Yokosaki, Monis et al. 1996). 
Analysis has also shown a significant correlation with tenascin C and the integrin 
αvβ6 which to our knowledge has not been shown previously. 
 
Finally data from a human PDAC RNA tissue microarray has confirmed that there 
is a significant positive correlation between lysyl-oxidase and tenascin-C 
expression in human PDAC. This finding supports the finding that lysyl-oxidase 
inhibition in the KPC model significantly decreases tenascin C expression. 
 
4.5 Lysyl-oxidase in PDAC 
The characteristic desmoplastic stroma found in PDAC has been implicated in 
promoting tumour growth, progression, invasion and metastasis. Recent studies 
have also suggested that the stroma functions to prevent drug delivery to the 
tumour epithelium (Provenzano, Cuevas et al. 2012). Lysyl-oxidase, an enzyme 
which catalyses the crosslinking of collagen and elastins, plays a central role in the 
generation and maintenance of this “stiff” desmoplastic stroma (Baker, Cox et al. 
2011).  
To date, lysyl-oxidase has been associated predominantly with the metastatic 
spread of cancers however through specific inhibition of lysyl-oxidase we have 
shown that it also plays a vital and ongoing role in an established primary tumour.  
Work in our lab has shown that inhibition of lysyl-oxidase alone increases survival 
in KPC mice and that combination with gemcitabine therapy further increases 
survival to a median of 226 days. 
Jen Morton and Bryan Miller in our lab have shown that expression of lysyl-
oxidase is high in all our mouse models of PDAC when compared with primary 
pancreatic ductal epithelial cells. Work by Jen Morton has shown that lysyl-oxidase 
expression is most significantly increased in those tumours that carry gain-of-
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function mutant p53. Interestingly this finding that lysyl-oxidase expression is 
highest in these tumours correlates with my work showing increased tenascin C 
expression in the same model. I have also shown that inhibition of lysyl-oxidase 
inhibits expression of tenascin C which again correlates with other work in the 
human PDAC RNA microarray that has shown that there is a strong positive 
correlation between lysyl-oxidase expression and tenascin C expression. These 
findings taken together are highly suggestive that lysyl-oxidase and tenascin C 
may play an important role in the mechanism through which gain-of-function 
mutant p53 (KPC) tumours are able to successfully metastasize to distant sites 
whereas tumours with only loss of p53 (KPflC) cannot.   
Work by Ewan McGhee, Paul Timpson and Jen Morton confirmed a significant 
decrease in collagen-crosslinking in Lox-Ab treated tumours through evaluation of 
the second harmonic resonance signal using multiphoton microscopy. This finding 
confirms the efficacy of the Lox-Ab being used in this study and the resultant 
“stromal softening”. 
Work undertaken in our lab has shown that in resectable human PDAC, lysyl-
oxidase expression correlates with expression of Hypoxia-inducible factor 1-alpha. 
The same work showed that high expression of both lysyl-oxidase and Hypoxia-
inducible factor 1-alpha signifies a bad prognosis in resectable human pancreatic 
ductal adenocarcinoma (See Fig. 41). This finding raises the interesting possibility 
that ultrasound elastography may provide a clinically useful biomarker which would 
mirror the lysyl-oxidase/HIF-1a axis and could be assessed utilising endoscopic 
ultrasound scanning in the clinic.  
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Figure 41: LOX expression and Hypoxia are significantly associated with 
survival in human PDAC.  
 
Kaplan-Meier survival analysis. There was a significant difference in survival between the Lox High 
and the Lox Low cohorts (Log-Rank p=8.1e-4) and patients with high levels of hypoxia also had 
significantly reduced survival (Log-Rank p=5.9e-4). (Figure and results courtesy of Jen Morton). 
 
 
 
 
 
 
 
 
 
 
 
 
 
It is well established that PDAC tumours have a poor vascular supply which leads 
to a state of hypoxia within tumours and has also been shown to limit drug delivery 
to tumour cells (Provenzano, Cuevas et al. 2012). Amy Au in our lab has shown 
that inhibition of lysyl-oxidase results in an increase in the intra-tumoural 
vasculature. This finding contradicts work that has shown that inhibition of lysyl-
oxidase leads to a reduction in the intra-tumoural vasculature (Osawa, Ohga et al. 
2013). It is possible that the reduction in the “stiffness” of the stroma due to lysyl-
oxidase inhibition permits increased migration of endothelial cells into the tumour 
thereby increasing blood supply to the tumour. It is also possible that the resultant 
stromal softening allows further opening of already existing vasculature, a 
mechanism highlighted in the context of hedgehog signalling inhibition (Olive, 
Jacobetz et al. 2009). 
The ability to stimulate angiogenesis is a process considered to be one of the 
major hallmarks of cancer (Hanahan and Weinberg 2000).  We might therefore 
find it concerning that a treatment aiming to treat cancer, through increasing 
vascular supply, is actually augmenting one of the processes considered 
fundamental to tumourigenesis. Contrary to this view we have shown that 
treatment with lysyl-oxidase alone significantly increases survival and more 
Normal Duct 
Lox Low 
Lox High 
Hypoxia Low 
Hypoxia High 
  
Lox medium Hypoxia medium 
Normal Duct 
Lox Low 
Lox High 
Hypoxia Low 
Hypoxia High 
  
 
Lox medium Hypoxia medium 
91 
 
importantly in combination with gemcitabine provides an additional survival 
advantage. 
This benefit may be explained by the selective increase in intra-tumoural necrosis I 
have shown in the Lox-Ab/gemcitabine combination treatment group. This 
increase in necrosis with the addition of gemcitabine suggests that lysyl-oxidase 
may be increasing delivery of gemcitabine to the tumour cells thereby triggering 
tumour cell death by necrosis. It is also well established that hypoxia itself can 
decrease the susceptibility of tumour cells to chemotherapeutic agents; therefore it 
is also possible that lysyl-oxidase by increasing tumour blood supply also 
decreases the tissue hypoxia and in so doing increases the sensitivity of the 
tumour to gemcitabine. 
In addition to the increased necrosis seen in the Lox-Ab/gemcitabine treatment 
group I have also shown an increase in the infiltration of intra-tumoural neutrophils 
and macrophages. It has been suggested that the poor vascular supply in PDAC 
may limit leukocyte infiltration in vehicle treated tumours however as this infiltration 
is not seen in KPC tumours treated with Lox-Ab alone it is likely that this infiltration 
is occurring in response to the significant intra-tumoural necrosis in the Lox-
Ab/Gemcitabine combination treatment group with leukocyte infiltration being 
aided by the increased tumour vasculature. 
As mentioned previously I have also shown that inhibition of lysyl-oxidase leads to 
dramatically reduced stromal tenascin C expression. It is possible that inhibition of 
lysyl-oxidase by increasing tumour vasculature in turn reduces tissue hypoxia 
thereby decreasing the drive for production of tenascin C. It is also possible that 
altered tissue “stiffness” reduces the expression of tenascin C by stromal cells. 
Additionally, tenascin C also has a large number of binding domains for 
extracellular matrix molecules such as fibronectin (Chiquet-Ehrismann 2004). As 
such it is possible that inhibition of lysyl-oxidase resulting in reduced crosslinking 
of collagen and elastin results in a significantly altered extracellular matrix 
architecture in which tenascin C is unable bind and interact in a normal manner. 
Finally as discussed previously I have shown that there is an increase in stromal 
tenascin C in response to gemcitabine treatment. Interestingly tenascin C has 
been shown to induce gemcitabine resistance in pancreatic cancer through 
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annexin II signalling in a PI3K/Akt/NF-kB dependent manner (Gong, Lv et al. 
2010). It is therefore possible that one mechanism by which lysyl-oxidase inhibition 
sensitizes PDAC to gemcitabine treatment in addition to increasing drug delivery is 
through the prevention of the protective upregulation of tenascin C.   
4.6 CXCR2 signalling in PDAC 
The role of CXCR2 signalling in epithelial cancers is well established and CXCR2 
and its ligands have been shown to be upregulated in both human disease and 
mouse models of PDAC (Takamori, Oades et al. 2000; Kuwada, Sasaki et al. 
2003; Hill, Gaziova et al. 2012; Ijichi, Chytil et al. 2011). Expression of CXCR2 is 
not limited to the PDAC tumour cells as a wide variety of cells including 
neutrophils, macrophages, endothelial cells and fibroblasts have been shown to 
express the receptor (Heidemann, Ogawa et al. 2003; Strieter, Burdick et al. 2006; 
Li, Cheng et al. 2011; Soehnlein, Drechsler et al. 2013; Hallgren and Gurish 2011; 
Ijichi, Chytil et al. 2011; Sharma, Nawandar et al. 2013; Feijoo, Alfaro et al. 2005; 
Marotte, Ruth et al. 2010). Given the high levels of expression of CXCR2 ligands 
and the widespread expression of the receptor; CXCR2 signalling has increasingly 
gained attention as a possible therapeutic target in pancreatic cancer.  
The expression of CXCR2 by a variety of cell types including the tumour cells 
themselves means that the effects of CXCR2 inhibition are potentially wide 
ranging within the tumour and its stroma.  
Inhibition of CXCR2 signalling in the KPC model of PDAC significantly increases 
survival (Colin Steele, personal communication). Furthermore combination therapy 
with gemcitabine provides a further but only moderate increase in survival. There 
is also no significant effect on tumour cell proliferation in response to CXCR2 
inhibition and I have shown that CXCR2 inhibition causes a dramatic increase in 
intra-tumoural necrosis with no alteration of tumour cell apoptosis.  
The expression of the CXCR2 receptor on endothelial cells and bone marrow 
derived endothelial progenitor cells is well characterised (Li, Cheng et al. 2011). 
The importance of CXCR2 signalling to the stimulation of angiogenesis in tumours 
is therefore of great importance. I have shown that inhibition of CXCR2 signalling 
with pepducin causes a significant reduction in the tumour vasculature. This 
reduction in vascular supply to the tumour may well be one of the important factors 
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triggering the dramatic increase in intra-tumoural necrosis. In contrast to this, Lox-
Ab treatment increases vascular supply resulting in increased drug delivery/ 
sensitivity and therefore increased necrosis. It is likely that the tumours which are 
characteristically hypovascular and hypoxic are on a knife-edge and through 
pepducin induced CXCR2 inhibition the decrease in tumour vasculature tips the 
tumour into a state of hypoxia in which tumour cells are no longer viable. Although 
results are preliminary it is interesting to note that constitutive knock out of the 
CXCR2 receptor in the KPC model of PDAC does not cause any significant 
alteration in tumour vasculature. The lack of suppression of tumour angiogenesis 
in this model may be due to the fact that, from early tumourigenesis tumours have 
developed in the absence of CXCR2 signalling and as such will have 
circumvented the requirement for CXCR2 signalling. Whereas pepducin induced 
CXCR2 inhibition was initiated after tumours had developed. Similarly, previous 
literature highlighting the importance of CXCR2 signalling in tumour induced 
angiogenesis has not evaluated tumour tissue that has developed in a CXCR2 -/- 
context and as such although they have shown that CXCR2 is vital to 
angiogenesis they do not prove that other mechanisms are not capable of fulfilling 
this role if required (Ijichi, Chytil et al. 2011). Utilising a pepducin molecule which 
inhibits CXCR2 signalling in the KPC model I have shown that CXCR2 signalling, if 
present during tumour development, is vital for triggering angiogenesis. 
Importantly work by others and results obtained in our pepducin treated mice have 
not shown that CXCR2 inhibition leads to a complete absence of vasculature in 
the tissues being investigated; therefore there must be other mechanisms capable 
of triggering angiogenesis in this context (Ijichi, Chytil et al. 2011). It is possible 
that although CXCR2 is the dominant receptor for proangiogenic ELR+ CXC 
chemokines other receptors such CXCR1 may still be able to play a significant 
role. Indeed CXCR1, although not the primary proangiogenic ELR+ chemokine 
receptor, is a receptor for a number of these chemokines (Strieter, Burdick et al. 
2006). Interestingly this raises the possibility that the CXCR2 inhibiting pepducin 
molecule used in this study may have additional minor inhibitory actions such as 
inhibition of CXCR1 signalling in addition to inhibiting CXCR2 which together 
results in greater inhibition of angiogenesis. In light of this it will be prudent to 
determine whether the pepducin used in this work has any effect on angiogenesis, 
as well as other parameters, in the KPC model on a CXCR2-/- background. In 
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addition to the CXCR2 and CXCR1 receptors there are also a variety of other 
ligands and receptors that have been shown to be important in triggering 
angiogenesis. For example CXCR4 and its ligand CXCL12 and nitric oxide 
synthase have been shown to have important roles in angiogenesis in 
xenotransplantation models of adenoid cystic carcinomas of the oral floor in mice 
(Takoaka, Hidaka et al. 2013). With further work the intricacies of the mechanisms 
of induction of angiogenesis utilised by tumours will be further clarified. It is likely 
that there are multiple pathways that tumours may utilise to trigger angiogenesis 
however given a greater understanding of these pathways the possibility of 
determining which signalling pathways are most important for angiogenesis in any 
given tumour may allow for patient and tumour specific targeted therapies.  
Interestingly given the massive increase in necrosis triggered by pepducin induced 
inhibition of CXCR2 signalling there is a trend towards decreased intra-tumoural 
leukocyte infiltration. Preliminary results indicate that this change is mirrored in 
KPC mice with constitutive knock out of CXCR2. The usual response to necrosis 
in vivo is the initial influx of neutrophils which are subsequently followed into the 
tissue by macrophages, a response that is conspicuously lacking in response to 
CXCR2 inhibition. We have shown that CXCR2 inhibition decreases the intra-
tumoural infiltration by leukocytes most likely by preventing leukocyte chemotaxis 
although it is possible that the reduced tumour vasculature also reduces the 
available window of entry for leukocytes into the tumour. This reduction of 
leukocytes is important but needs further investigation as the role of intra-tumoural 
leukocytes is highly context dependent and they may be either anti or pro-
tumourigenic. It has been shown that neutrophils and macrophages may exhibit 
either an N1/M1 anti-tumour phenotype or an N2/M2 pro-tumourigenic phenotype 
in response to polarizing cytokine signalling with macrophages for example in 
response to IL-10 and TGFβ signalling switching from an M1 to M2 phenotype 
(Sica and Mantovani 2012). It will therefore be interesting to determine whether an 
alteration in leukocyte phenotype occurs in response to CXCR2 inhibition.  
Macrophages and neutrophils have also both been shown to play important roles 
in angiogenesis (Sica and Mantovani 2012; Tazzyman, Lewis et al. 2009) and the 
reduction in tumour vasculature by CXCR2 inhibition may in part be due to the 
reduction in intra-tumoural leukocytes.  
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Macrophages and neutrophils have additionally been shown to promote tumour 
cell migration and invasion through release of enzymes such as MMPs and 
through opening holes in vessel basement membranes on extravasation (Smith 
and Kang 2013). Therefore reduction in intra-tumoural leukocyte numbers may 
additionally reduce the invasive and metastatic potential of a tumour which in 
addition to the reduced vascular window due to decreased vessel numbers may in 
part explain the reduced metastatic spread noted with CXCR2 inhibition in our 
model (Tazzyman, Lewis et al. 2009; Bohrer, Schwertfeger et al. 2012).  
In addition to reduced vasculature and leukocyte infiltration, CXCR2 inhibition 
caused a reduction in the number of myofibroblasts and amounts of collagen and 
elastin within treated tumours. It has been shown by others that CXCR2 signalling 
between tumour epithelium and fibroblasts leads to connective tissue growth factor 
(CTGF) expression which is important to tumour progression (Ijichi, Chytil et al. 
2011). The importance of the desmoplastic stroma to PDAC is well established 
and therefore any reduction in the stroma likely has a significant effect on the 
viability of the tumour. 
Interestingly, given the reduced stromal cell population in response to CXCR2 
inhibition, expression of tenascin C is markedly increased. Tenascin C is involved 
in tumour progression and maintenance, angiogenesis, metastasis migration and 
invasion. It is produced in a variety of situations including mechanical stress and 
hypoxia (Jones and Jones 2000). The increase in tenasin C expression in this 
instance is most likely a stress response as a result of decreased tumour 
vasculature resulting in tissue hypoxia which is driving production. The increased 
tenascin C is likely providing tumour epithelium with support for example through 
attempts at stimulating angiogenesis and through augmentation of WNT and 
Notch signalling. Finally we have shown that combination with gemcitabine again 
causes a further increase in tenascin C production as noted in our work 
characterising stromal changes elicited by lysyl-oxidase inhibition. As discussed 
previously this may be additional evidence of a tenascin C induced mechanism of 
gemcitabine resistance.     
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4.7 The interlinked roles of lysyl-oxidase, CXCR2 and tenascin C in PDAC 
The tumour microenvironment is an extremely complex “ecosystem” in a constant 
state of flux (Feig, Gopinathan et al. 2012). Within the microenvironment there are 
many factors seemingly essential for the maintenance of tumour cell viability 
however there is also extreme plasticity within the microenvironment allowing for 
continuous tumour adaptation and survival. The cellular and protein constituents of 
the microenvironment and the pathways that control them are complex and 
interlinked but crucial to this plasticity. CXCR2, lysyl-oxidase, tenascin C and 
hypoxia appear to be central components with significant roles within the tumour 
microenvironment (see Fig. 42) which is itself considered to promote 
tumorigenesis, maintenance of tumour cell viability, drug resistance and 
metastasis.          
 
Figure 42: The roles of Lysyl-oxidase, CXCR2 and Tenascin C in PDAC 
Summary of the roles of lysyl oxidase, CXCR2 and tenascin C as highlighted in this work. 
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Future Work 
Through the work undertaken in this thesis I have developed more robust methods 
for histological characterisation of stromal constituents in tumour tissues. I have 
shown that tenascin C is important in human PDAC having a significant effect on 
survival in patients and significantly correlating with hypoxia, lysyl-oxidase 
expression, differentiation and possibly invasive behaviour. I have also shown that 
it is produced and potentially has important roles in the KPC model of PDAC that 
mirror those found in human disease. In agreement with others we have shown 
that the stroma in PDAC is a useful and effective therapeutic target. We have 
shown that both CXCR2 inhibition and lysl-oxidase inhibition have significant 
effects on survival in KPC models of PDAC. I have also highlighted significant 
effects on tenascin C expression in the context of CXCR2 inhibition and lysyl-
oxidase inhibition.  
In the lab we are currently generating a cohort of tenascin-C knock out KPC mice 
which will allow us to assess the survival benefit in PDAC. From these mice it will 
be possible to generate tenascin C knock out KPC PDAC cell lines with which, in 
conjunction with tenascin C-/- and tenascin C +/+ allograft recipients, we will be 
able to further characterise the importance of tumour derived tenascin C as 
opposed to that produced by the stroma. The observation that tenascin C is 
upregulated in response to gemcitabine treatment also requires further 
assessment, specifically in reference to the mechanism by which lysyl-oxidase 
inhibition in combination with gemcitabine treatment triggers PDAC tumour cell 
necrosis. Tenascin C may also be a potential target in combination with other 
treatments. For example in pepducin treated KPC mice where there is an 
upregulation of tenascin C in response to CXCR2 inhibition as a result of hypoxia, 
tenascin C is likely playing a tumour supportive role. It will therefore be vital to 
determine the effects of CXCR2 inhibition in tenascin C knockout KPC models of 
PDAC or in combination with lysyl-oxidase inhibitors. The role of tenascin C and 
lysyl-oxidase in mutant p53 mediated metastasis is also potentially of great 
importance. Given that in the non-metastatic p53 null (KPflC) mouse model of 
PDAC there is minimal production of tenascin C and lysyl-oxidase evaluating the 
effect of overexpression of tenascin C and/or lysyl-oxidase in p53 null (KPflC) 
PDAC cell line xenografts and allografts will be of great interest.  
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I have also shown that CXCR2 inhibition significantly decreases the number of 
myofibroblasts in KPC PDAC models. Unfortunately I was unable to fully 
characterise the source of these myofibroblasts. It is generally accepted that 
pancreatic stellate cells are the source of myofibroblasts in PDAC (Apte, Park et 
al. 2004). This is a finding that we were unable to confirm. Work to attempt to 
lineage trace these cells is necessary and is ongoing in the lab. This work will 
allow clarification of the specific contribution pancreatic stellate cells make to the 
generation of the characteristic desmoplastic stroma in PDAC and allow 
characterisation of the changes that occur in this population of cells by stroma 
targeted therapies. This will be particularly important given the early work being 
undertaken by Fearon et al. which is highlighting the potential significance of a 
FAP alpha positive “stellate cell” population, the ablation of which results in T cell 
mediated immune control of the growth of pancreatic ductal adenocarcinoma 
(Kraman, Bambrough et al. 2010). 
Finally the failure of the human trial of IPI-926, a SHH inhibitor, likely highlights the 
need to fully and carefully evaluate stromal changes in response to targeted 
therapies in order to highlight robust alterations which are likely to represent 
significant changes relevant to human disease (Infinity pharmaceuticals. http://phx.corporate-
ir.net/pheonix.zhtml?c=12194&p=irol-newsArticle&ID=1653550&highlight= (accessed 09.08.13)) This we believe is 
achievable utilising the thorough methods that we have established.  
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